Agrify Corporation Announces $3.4 Million Sales Order From New Jersey Woman-Owned Business HarvestWorks Farm
Agrify Corporation Announces First Multi-Year and Two-Million Dollar Extraction Managed Services Contract with Customer in Michigan
Gross Profit is expected to increase 105% to $1.9 million, compared to $1 millionin Q3 2023
Q4 2023 Net Cash burn is also expected to be the lowest in the Company history, and the Company expects to be in a position to approach cashflow break-even in the second half of 2024
Agrify’s Enters Into First Hydrocarbon Extraction Lab & Vertical Farming Unit Facility in California
Hello Everyone,
We have another new profile that we anted you to research for Friday’s session. This is a company that we have never profiled in the past but are excited to do so.
We have seen some exciting profiles in February that have shown us some serious movement. Today’s profile (Thursday) opened up at 2.07 after closing at 1.98 on Wednesday. We saw it breakout and hit highs of 2.57 shortly before 1 pm for a massive 25% move off the open in one session. We have seen some other big movers in Feb that I will update you on over the weekend before my next profile
Pull up AGFY immediately.
Agrify is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Our proprietary micro-environment-controlled Vertical Farming Units (“VFUs”), enable cultivators to produce the highest quality products with unmatched consistency, yield, and ROI (return on investment) at scale. Our comprehensive extraction product line, which includes hydrocarbon, ethanol, solventless extraction, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates.
We saw this one explode all the way up to .74 on huge interest during Thursday’s session are releasing explosive news that caught The Street’s attention, causing it to have the company’s 2nd highest volume in the past year.
Agrify Corporation Announces $3.4 Million Sales Order From New Jersey Woman-Owned Business HarvestWorks Farm
Deal Includes Additional Multi-Year Production Success and SaaS Fees
TROY, Mich., Feb. 29, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the signing of a multi-year cultivation and extraction deal with HarvestWorks Farm, New Jersey(“HarvestWorks Farm” or the “Customer”), a licensed New Jersey operator. The multi-faceted transaction includes a $3.4 million cultivation and extraction order for 156 of Agrify’s Vertical Farming Units (or “VFUs”) and a complete Turnkey Pure Pressure Solventless extraction Lab Package, a 2-year Service Support Agreement at $350 per pound Production Success Fees (or “PSF”), and a 5-year of approximately $1 million SaaS Fee Agreement.
HarvestWorks Farm is a woman-owned company founded by CEO and entrepreneur, Rita Ruggieri, a New Jersey resident. HarvestWorks Farm was one of the first operators licensed for cannabis cultivation and manufacturing in the Garden State and is dedicated to the cultivation and processing of exceptional quality cannabis products for provisioning centers and distributors as a wholesale contract manufacturer as permitted by the state of New Jersey Cannabis laws and regulations.
Raymond Chang, Chairman and CEO of Agrify, shared that “Agrify is pleased to have the opportunity to work with Rita and her amazing team at HarvestWorks Farm in this fast-growing and exciting new market. Rita is a proven, successful, and an award-winning serial entrepreneur with deep knowledge and passion in the Cannabis industry. Agrify is excited to be HarvestWorks’ partner of choice. Together, we will work to bring the some of the most innovative and high-quality products to the Garden State.”
HarvestWorks Farm has recently completed their 6-day on-site advanced solventless training program with the Senior Training Manager for Solventless Extraction. During the course of the training program, Agrify’s team guided HarvestWorks Farm’s staff through production and manufacturing of some of the most unique and exciting Live Resin and Live Rosin concentrates the market. The HarvestWorks Farm team was trained in all processes relating to Hash Washing, Freeze Drying, Pressing, Jar Tech, Mechanical Separation, and Vape Cart Formulation techniques to produce the finest quality Ice Water Hash, Live Rosin, Jam, Diamonds, Sauces, Rosin Vape Pens, and other textures. HarvestWorks aims to introduce a multi-faucet of products into the New Jersey market by early summer of 2024.
In addition, HarvestWorks Farm will be deploying 70 double stacked VFUs in their approximately 20,000 square feet (about four times the area of a basketball court) building in conjunction with their extraction lab. Phase two of the operation will include another approximately 80+ VFUs in an adjacent building. HarvestWorks Farm has elected Agrify’s Service Support Program whereby a dedicated Agrify Customer Success Manager will be on site to provide operational support, optimizations, and quality control during the first two years of operation. In return, Agrify would receive a yield-based Production Success Fee of $350 per pound of flowers produced. Agrify estimates that the VFU would produce an average of 40 pounds of top-quality flowers per year.
“Agrify’s team has been a pleasure to work with – from designing and engineering to installation of the equipment in our facility. HarvestWorks Farm is excited to optimize strain specific recipes in Agrify’s VFUs, coupled with the data from Agrify Insights software, to produce scalable, consistent, and high-quality cannabis products for a young, dynamic, and rapidly growing New Jersey adult market” said Rita Ruggieri, CEO of HarvestWorks Farm.
Agrify Corporation Announces First Multi-Year and Two-Million Dollar Extraction Managed Services Contract with Customer in Michigan
TROY, Mich., Feb. 22, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the signing of a term sheet with PDS Ventures, LLC (“PDS Ventures” or the “Customer”), a licensed Michigan operator, to provide PDS Ventures with Agrify’s multi-year end-to-end managed extraction services (“Managed Services”).
Agrify’s Managed Services is a first-of-its-kind program where Agrify leases turnkey extraction and post-processing lab equipment to qualified operators and provides a full-time customer success specialist to guide and manage extraction-related operations for the customer. The customer success specialist will be on-site at the customer’s facility to provide hands-on support, training, and guidance on how to adhere to standard operating procedures of a full suite of extraction equipment. Managed Services allows Agrify to significantly increase the average lifetime value of our customers. Instead of just selling the hardware, this new innovative partnership allows Agrify to invest alongside qualified operators and enjoy multi-year high margin revenue. Operators also benefit from Agrify’s professional design, support, installation, and ongoing training and SOP enforcement to ensure maximum yield and results.
The multi-year Managed Service contract allows Agrify to collect a monthly production success fee based on the actual amount of finished product produced and a monthly management fee during the duration of the contract term. Agrifycould potentially earn up to $2 million throughout the lifetime of this multi-year managed service contract with PDS Ventures.
“We are extremely excited to launch our end-to-end managed service contract with PDS Ventures,” said Brian Towns, EVP & General Manager of Agrify. “We have been planning for the launch of this industry-first end-to-end managed extraction service for some time and it is only possible with the combination of our proprietary managed software and the multiple extraction solutions now under Agrify. Together, we believe PDS Ventures will become one of the most successful extraction operators in the State of Michigan.”
PDS Ventures has signed a 3-year contract with Agrify and together, Agrify and PDS have elected to deploy Agrify’s PX10 Hydrocarbon Extraction System, Hydrocarbon Distillation Unit (HDU), and Diamond Miner from Precision Extraction. The post-processing capabilities have been enhanced by the selection of a HIVE15 Thin Film Distillation System from Lab Society, and to scale solventless processing, the Axis Trichome Separator turn-key package which includes a Pikes Peak Rosin Press.
“We are confident that Agrify’s Managed Services program will be a game-changer for our business,” said Daniel Yatooma, Partner at PDS Ventures. “With Agrify’sexpertise and support, we are excited to expand our extraction capabilities and bring even higher-quality products to our customers.”
Agrify Corporation Announces Preliminary Unaudited Financial Results for Q4 2023 and Update on Customer Project
Expects to Achieve the Lowest Record Net Loss and Cash Burn in Company History
TROY, Mich., Feb. 21, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced preliminary unaudited financial results for the fourth fiscal quarter of 2023 and updates for its Ocean Deep/Golden Lake Business Park project.
Fourth Quarter 2023 Outlook
Net Loss in Q4 2023 is expected to be at a historical low of $750 thousand, compared to $2.1 million net loss in Q3 2023, and $58 million loss in Q4 2022.
Loss from Operations is expected to decrease by 46% to a historical low of $2.5 million, compared to $4.6 million in Q3 2023
Gross Profit is expected to increase 105% to $1.9 million, compared to $1 millionin Q3 2023, and a gross loss of $33.5 million in Q4 2022.
Q4 2023 Net Cash burn is also expected to be the lowest in the Company history, and the Company expects to be in a position to approach cashflow break-even in the second half of 2024.
Agrify is expected to release its financial results for the fourth quarter and full fiscal year ended December 31, 2023 before the end of March 2024. The financial information presented in this press release may be adjusted as a result of the completion of customary annual review and audit procedures.
Golden Lake Business Park Project Update
Agrify’s customer, Ocean Deep/Golden Lake Business Park, is a California-based vertically integrated cannabis operator. Ocean Deep has completed the purchase of a roughly 30,000 square feet facility in Adelanto, California, and is currently constructing Agrify’s UL-Certified EXP1 Explosion Proof Room. Ocean Deep expects to soon be extracting products with Agrify’s turnkey PX30 Hydrocarbon Extraction Lab Package to bolster its product offerings. Ocean Deep is also expected to begin operation with an estimated 120 Vertical Farming Units (“VFUs”) sold by the Company to produce high-quality cannabis flower in 2024.
Agrify’s Enters Into First Hydrocarbon Extraction Lab & Vertical Farming Unit Facility in California
TROY, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced it has entered into a multi-million dollar sales agreement (“the Agreement”) with Ocean Deep/Golden Lake Business Park, a California-based vertically integrated cannabis operator. Ocean Deep will be extracting products with Agrify’s turnkey PX30 Hydrocarbon Extraction Lab Package to bolster its product offerings. Ocean Deep is also expected to begin operation with an estimated 120 Vertical Farming Units (“VFUs”) sold by the Company to produce high-quality cannabis flower in 2024.
The PX30 Hydrocarbon Extraction System is the largest system of Agrify’s PX-series. The PX30’s four 7.5 lbs. material columns can be run in parallel, allowing a complete 30-pound batch cycle in under 60 minutes, and making it one of the largest and fastest extractors on the market with up to 240+ lbs. per 8-hour shift. This robust system is poised to offer enhanced capabilities for hydrocarbon extraction, catering to the demands of commercial operators focusing on large-scale batch processing and extracting for the creation of direct-to-consumer products.
Raymond Chang, Chairman and CEO of Agrify, shared that “We are very excited to announce this agreement for the sale of our first combined VFU and PX30 Hydrocarbon Extraction Lab facility in the state of California. We applaud our partner Ocean Deep/Golden Lake Business Park’s foresight for selecting Agrify’s technologies in the fiercely competitive California market. We believe our superior cultivation and extraction technologies will allow Ocean Deep to offer the highest quality and most consistent products to its customers.”
The addition of Agrify’s UL-compliant Explosion Proof (EXP) Rooms was, the Company believes, an ideal choice for Ocean Deep’s C1D1 extraction lab. Agrify’s safe and easy to install C1D1/C1D2 extraction rooms are designed to be easily set up in less than one day and are equipped with a PSI technical report certification for professional engineers to field verify in all 50 states.
“As CEO of Ocean Deep/Golden Lake Business Park, it is with great enthusiasm that I disclose our new alliance with Agrify, renowned for their trailblazing cannabis cultivation and extraction innovations. Our southern California operations will proudly serve as a showcase for their end-to-end cannabis solutions,” said Mr. Sun, CEO of Ocean Deep/Golden Lake Business Park. “We chose Agrify because their approach to the industry is grounded in science and focuses on efficiency which resonate with our mission to redefine industry benchmarks through the adoption of forefront technologies that amplify our production capabilities and assure superior product quality. We look forward to the advancements and triumphs that our combined efforts will yield.”
These industry developments illustrate the continuous innovation and commitment to safety within the cannabis sector as Agrify adapts to expanding market demands.
EVP, Chief Science Officer, and GM Cultivation Division
Brian Towns
EVP & GM Extraction Division
Sheryl Elliott
Senior Vice President of Human Resources
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND USD BY SHORE THING MEDIA LLC FOR A ONE DAY AGFY AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
INDP Has $16 Million in Cash and Equivalents as of 9/30/23, With a Market Cap of Just $15 Million
Top line data from the INDP-D101 trial of lead compound Decoy20 was presented at the Society of Immunotherapy in Cancer on November 4, 2023. In addition to the safety data and immune response reported previously, the Company reported that all four patients had achieved and continue to maintain stable disease, three of whom presented with progressive disease.
The Company announced the initiation and first dosing of the second cohort of its INDP-D101 trial, which will be administered at a lower dose and is expected to bring the Company closer to determination of the recommended Phase 2 dose for the multi-dosing part of the trial
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Over the past 12 months we haven’t seen any insider selling. We did see one substantial Insider purchase over over 100K shares at 2.34, which are at moderately higher levels than it is currently sitting.
SCIENCE & PIPELINE
Novel Insights. Novel Therapies.
Historically, we know that tumor regression has been observed in the presence of bacterial infection. We also know that bacteria contain immune system danger signals, called pathogen-associated molecular patterns (PAMPs), that collectively can activate all of the cellular components of our innate and adaptive immune pathways. PAMPs are recognized by receptors, such as Toll-like (TLR), NOD, STING and RIG-I, that are found on and involved in activation of many different innate and adaptive immune cells.
Our platform is based on the hypothesis that highly efficient anti-tumor immunotherapy will require safe activation of both innate and adaptive cellular immunity in both tumors and immune organs, and that this might be achieved with a multi-targeted package of bacterial PAMPs, in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. While current therapies are increasingly becoming more and more personalized and costly, we are advancing an approach designed to be widely accessible, with broad anti-tumor and anti-viral activity not dependent on the targeting of specific tumor or viral antigens.
Current Approaches
Current immunotherapies only cure a very small percentage of advanced cancer patients because they activate only one or a few innate or adaptive immune cell types.
The Indaptus Approach
Goal: to safely and effectively activate both innate and adaptive cellular anti-tumor pathways by passively targeting both the tumor and immune organs.
A Unique Approach
Previous research has shown that lipopolysaccharide (LPS), an endotoxin that binds to Toll-like receptor 4 (TLR4), is a key bacterial PAMP that activates the immune system. Activated TLR4 has been shown to play a role in dendritic cell activation and T-cell-mediated anti-tumor immune responses. Our novel insights have enabled us to create attenuated and killed, non-pathogenic gram-negative bacteria with unique levels of LPS – levels that have now been shown in pre-clinical studies to be sufficient to synergize with other PAMPs in the bacteria to safely prime and/or activate innate and adaptive immune pathways. We currently have a broad patent portfolio with 34 issued or granted patents that are based on the technology originally developed by our Founder and Chief Scientific Officer, Dr. Michael Newman, at Indaptus’ predecessor company, Decoy Biosystems.
Based on our successes to date, we are now building a pipeline of therapeutic candidates designed to be delivered intravenously, targeting cancers and infectious diseases with high unmet medical needs.
Results to Date
We are currently advancing our lead candidate, Decoy20, through Phase 1 clinical trial. To date, Decoy20 and/or related candidates have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models, including high percentage complete and durable anti-tumor responses in combination with different classes of existing therapeutics.
In oncology, Decoy candidates have demonstrated the ability to eradicate established tumors in a murine model of hepatocellular carcinoma in combination with either a non-steroidal anti-inflammatory drug (NSAID) or an anti-PD-1 agent, and more efficiently with both. Tumor eradication has occurred with a wide therapeutic index and has led to induction of 100% immunological memory. In combination with low-dose chemotherapy, Decoy candidates have also produced highly efficient eradication of established tumors in a mouse model of non-Hodgkin’s Lymphoma (NHL), also with induction of immunological memory. Combination-mediated tumor eradication has also been observed with a human tumor xenograft NHL model with inclusion of a targeted antibody. Decoy candidates have also produced significant single agent activity in murine models of both metastatic pancreatic carcinoma and orthotopic, colorectal carcinoma.
In infectious disease, single agent Decoy therapeutics have produced significantly broader activity than standard of care treatment in a pre-clinical model of chronic Hepatitis B infection, as well as single agent activity against chronic HIV infection in a pre-clinical humanized mouse model.
Generation and/or activation of the cells required for innate and adaptive anti-tumor and anti-viral immune responses takes place, to a significant extent, outside of the tumor or sites of infection, including in the spleen. Our intravenous therapeutic candidates are expected to passively target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and HBV infection, the liver. As our therapeutic candidates are expected to be cleared very quickly by the liver and spleen, we anticipate a low risk of non-specific autoimmune side effects relative to other types of immunotherapies designed for continuous exposure.
We have initiated our Phase 1 clinical trial of Decoy20 in December 2022 and dosed our first patient in March 2023.
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
PUBLISHED
JAN 4, 2024 8:00AM EST
Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc.(Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate stabilized packages of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces that the European Patent Office (EPO) has informed the company that it will grant a European patent related to the company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections.
The patent, titled “Methods of Treatment of Infections Using Bacteria,” (Application 19 866 580.4) provides protections for the application of the Company’s Decoy technology platform alone or in combination with standards of care for the prevention or treatment of any viral infection. The EPO patent will be the second patent granted to Indaptus outside the United States for this application.
Jeffrey Meckler, Indaptus Therapeutics CEO, commented, “The continued protection of our intellectual property both in the U.S. and abroad will provide a competitive advantage for the Company, which should ultimately drive significant shareholder value over time. We continue to explore the applications of our technology platform beyond solid tumors, for which we are currently engaged in a Phase 1 clinical trial, and look forward to updating our shareholders on scientific progress.”
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
PUBLISHED
NOV 6, 2023 8:00AM EST
Poster presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer Showed Favorable Safety Profile and Achievement of Stable Disease in All Four Patients in First Cohort.
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc.(Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. A broad expression of cytokines and chemokines associated with innate and adaptive anti-tumor immune responses was observed, while adverse events were generally tolerable and resolved within 30 minutes to three days. Decoy20 is designed to “re-set” the immune system’s response to cancer. The poster was presented on November 4, 2023, at the Society for Immunotherapy of Cancer in San Diego.
“We are impressed that we saw short-term induction of more than 50 cytokines, chemokines and biomarkers and believe this is unprecedented with a single agent. These early data support our long-standing hypothesis that the Decoy platform may induce robust immune responses across multiple types of immune cells that we believe are important for the eradication of solid tumors,” commented Indaptus CEO Jeffrey Meckler.
“The relatively brief duration of exposure to Decoy20 supports our hypothesis of utilizing a “pulse-prime” approach, providing a short period of activation to avoid unwanted toxicities that may occur from prolonged immune activation,” commented Michael Newman, Ph.D., Indaptus Founder and Chief Scientific Officer.
As reported in the poster, trial subjects experienced transient induction of over 50 different biomarkers associated with immune responses, and generally anticipated transient adverse events.After the end of infusion, Decoy20 was cleared from the blood within 30 to 120 minutes. This rapid clearance and associated transient cytokine/chemokine induction are desired to avoid prolonged toxicity, often associated with longer term cytokine exposure. In contrast, therapeutics that are designed to be continuously present over weeks, months, or even years, such as CAR-T, can induce this type of toxicity. Peak cytokine and chemokine induction occurred within ~4 to 24 hours and most returned to baseline by 24-48 hours. Lymphocyte cell populations were transiently reduced in the blood and then rebounded, suggesting that these critical immune cells were redistributing from the circulation to lymph nodes, immune organs or sites of tumor. This supports the hypothesis of an “immune resetting” proposed mechanism of action.
In addition, each of the subjects was observed to have stable disease four weeks after a single dose, with three of them having started the trial with progressive disease.
“We look forward to continuing the trial with the current cohort having a lower dose, given the broad potential immune activation we have observed,” added Roger Waltzman, M.D., Indaptus’ Chief Medical Officer. “We anticipate that in the next stage of the trial we will assess the effect of weekly dosing (as opposed to the single dose in these first two cohorts), while analyzing a host of biomarkers, immune and tumor cells in peripheral blood, and immune cell populations in the tumor microenvironment, coupled with standard radiographic measurements.”
The poster was titled, “Preliminary results of an in progress, first-in-human Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.” First cohort patients received a single dose of 7×107 killed Decoy20 bacteria via a one-hour IV infusion.
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
PUBLISHED
OCT 31, 2023 9:01AM EDT
Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc.(Nasdaq: INDP) announces it will be presenting interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data, released today in abstract form, demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20. The data in full will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) on November 4. The conference will be held from November 1-5, 2023 in San Diego.
Michael J. Newman, Ph.D., Indaptus’ Founder and Chief Scientific Officer noted, “Even in this early study, Decoy20 is exceeding our expectations from the perspective that we are seeing activation of the immune system, based on transient expression of multiple plasma cytokines and chemokines, with expected transient adverse events. These results, in conjunction with the desired and observed rapid clearance of Decoy20 from the blood, are highly supportive of our “Pulse-Prime” hypothesis for the Decoy20 mechanism of action.”
Roger Waltzman, M.D., Indaptus’ Chief Medical Officer, added, “We are encouraged by the tolerability of Decoy20 and the notable evidence for broad immune biomarker activation at this early stage. At one month following the single dose of Decoy20, all four of the first cohort patients had stable disease. We are following these patients as well as working on enrolling the second cohort, which utilizes a lower dose. This lower dose is based on the pharmacodynamic results seen with the first cohort and plans to optimize Decoy20 for both weekly dosing and combination approaches.”
The abstract/poster is titled, “Preliminary results of an in progress, first-in-human Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.” First cohort patients received a single dose of 7×107 killed Decoy20 bacteria via a one-hour IV infusion. As of August 31, 2023, treatment-related adverse events, potentially expected based upon prior clinical studies with purified lipopolysaccharide, have included, among other events, changes in hemodynamic parameters, transaminase elevations, and lymphopenia; all resolved with or without treatment within 30 minutes to 3 days. The Company believes the short half-life of Decoy20 observed in blood coupled with the marked, but transient, induction of multiple cytokines and chemokines over approximately 24 hours supports the PK “pulse” and PD “prime” hypothesis for the Decoy20 immune-oncology strategy.
Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.
MICHAEL J. NEWMAN, PH.D.
Founder and Chief Scientific Officer
A founder of the company, Dr. Michael Newman currently serves as our Chief Scientific Officer. Most recently, he was Founder and CEO of Decoy Biosystems, where he developed the technology that serves as the foundation of Indaptus. With more than 35 years of experience carrying out and managing oncology drug discovery through early development in academia and at pharmaceutical and biotechnology companies, Michael has also served as a consultant to ~35 companies, assisting with target identification and prioritization, management of R&D, fundraising, and in/out-licensing. His previous positions include faculty appointments in biochemistry at Brandeis University and the Roche Institute of Molecular Biology, Senior Associate Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), Executive Director of Oncology at Novartis Pharmaceuticals (Head of Cancer Biology in the U.S.), and senior management positions at several Biotechnology companies, where he also managed drug discovery programs in inflammation, diabetes, and infectious disease. Michael received a Bachelor’s degree in biology from the University of California at San Diego, a Ph.D. in cell and developmental biology from Harvard Medical School (National Science Foundation Pre-doctoral Fellow) and carried out post-doctoral research at Cornell University.
WALT A. LINSCOTT
Chief Operating Officer
Walt Linscott brings more than three decades of global leadership, entrepreneurial and professional experience with broad business development, operational, regulatory, and transactional experience in the Life Sciences sector to his current role as Chief Operating Officer at Indaptus. Most recently, he held the position of Chief Business Officer at the company. Prior to Indaptus he was the Chief Business Officer at Intec Pharma. He is also a Founding executive member of Oxford Strategic Alliance, a multinational business development and referral enterprise for strategic advice, management and investment development/management for individuals and companies that are globalizing. Previously, Walt served as President, COO and General Counsel at Treiber Therapeutics, an anti-viral-focused venture he co-founded. He has also served in a variety of General Counsel and Corporate Secretary roles at Cocrystal Pharma, Carestream Health, and Solvay Pharmaceuticals, where he also led compliance, IP, security, privacy, public affairs and government affairs functions. In addition, he was previously an Associate and Partner at Thompson Hine where he founded the firm’s Atlanta office, served as Partner in Charge, and as Chair of the firm’s Life Science Practice Group. Walt holds a Master of Science in Experimental and Translational Therapeutics with honors from the University of Oxford, a Master’s degree in Global Business from the University of Oxford and Master’s degree in Entrepreneurship from Cambridge University. He earned his J.D. from the University of Dayton School of Law where he served as Managing Editor of the Law Review. After graduating with a Bachelor’s degree from Syracuse University and prior to entering law school, he earned a commission and served on active duty as an Officer in the United States Marine Corps. Walt is also a Certified Flight Instructor and was previously a professional stunt pilot.
ROGER J. WALTZMAN
Chief Medical Officer
Roger Waltzman, M.D., M.B.A. currently serves as our Chief Medical Officer. Dr. Waltzman is a board-certified medical oncologist whose career highlights include the roll of Chief Medical Officer of publicly traded company, Molecular Templates (2019-2023) and multiple senior drug development roles at Novartis Oncology (2007–2013), where he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development Head of Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix (now Inspirna), where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals, where he led scientific aspects of development and commercialization of Mytesi® (crofelemer).
Before joining the industry, Dr. Waltzman held assistant professorships in medical oncology and palliative care at Saint Vincent’s Hospital and Mount Sinai School of Medicine in New York. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned a Master of Business Administration at Columbia Business School and a Doctor of Medicine and Bachelor of Arts from Brown University.
NIR SASSI
Chief Financial Officer
Nir Sassi currently serves as our Chief Financial Officer, bringing a broad skillset across management, corporate finance, due diligence, accounting, and financial analysis. Prior to joining Indaptus, Nir spent 11 years at Intec Pharma, starting as Vice President of Finance and ending his tenure there as Chief Financial Officer. Previous to that, Nir served as a Senior Manager at PricewaterhouseCoopers Israel for eight years, including two years relocation to the PWC New York office. He is a certified public accountant in Israel and holds a Bachelor’s degree in economics and accounting from Ben Gurion University in Beer Sheva, Israel.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY INDP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Iveda Awarded $3.2M Contract for Confidential Application by Taiwanese Government Agency
IVDA Boasts several recent global contract wins, including expansions in Egypt and deals in the Philippines and Vietnam––worth millions of dollars of revenues and gross profits to Iveda in 2024 and recurring revenue for years to come
Iveda® has been offering cloud video surveillance technologies to service providers. Today, Iveda is at the forefront of Digital Transformation of many cities across the globe. Our IoT platform with smart sensors and devices were specifically developed for service providers for smart home and smart city solutions. Likewise, our IvedaAI™ intelligent video search technology adds critical intelligence to normally passive video surveillance systems.
David Ly, our visionary chairman and CEO, founded Iveda in 2003. Under his leadership, Iveda has evolved into a mature, global organization, partnering with service providers for mass distribution of cloud video surveillance as service, utilizing our Sentir platform. Iveda continuously innovates and remains committed to our vision of providing cloud-based technology on a global scale.
Our core values and commitment to excellence define the framework and alignment of our fundamental business strategies and ethical practices. We earned our continued success through our dedication to customer satisfaction and ethical standards of honesty, integrity, and mutual trust.
At Iveda we believe that our success depends on putting our customers first. By paying close attention to customers’ needs, we are able to respond with the best products and services.
Iveda is based in Mesa, Arizona with a wholly-owned subsidiary in Taiwan. Iveda has been a publicly-traded company since 2009, under the ticker symbol IVDA.
According to The Maxim Group Equity Research Analyst,Iveda Solutions, Inc. (NASDAQ: IVDA) has +300% upside potential, based on the analysts’ $3.00 price target.
Not only are their technicals screaming breakout, the company also just released big news which is about to start gaining the streets attention!
The Company has several potential bullish catalysts in play right now, and is on the verge of Disrupting a $5.6 Bln Global AI in video surveillance industry with exciting news just announced.
Iveda announced JV (joint venture) to partner with 100 Philippines government units across the region to modernize key infrastructure for improved public safety and more. Following the success of its Iveda Safe City presentations throughout 2023, with cities across the nation witnessing the potential of Iveda’s innovative solutions, several city budgets across the region are gearing up to integrate IvedaAI into their operational frameworks in 2024.
Cities in this initiative include Cebu (the largest in the Philippines), Bacolod, Iloilo, and Davao, marking a significant stride towards a safer and more technologically advanced urban landscape.
As Iveda continues enabling metropolitan areas across the globe to achieve true smart city status, Iveda Philippines remains critical in the facilitation of relationships necessary to execute mutually beneficial, long-term contracts.
Bolstering Philippine President Ferdinand “Bongbong” Marcos Jr.’s efforts to drive infrastructure development in the region, this JV reflects the strong commitment from cities to leverage Iveda’s AI solutions, emphasizing their trust in the capabilities of the technology, particularly to enhance public safety and city management.
“This ambitious goal underscores Iveda’s dedication to driving advancements in AI technology and making a substantial impact on the landscape of smart cities in the Philippines,” said David Ly, Iveda CEO and founder. “As the nation moves towards embracing cutting-edge technologies, Iveda Philippines stands at the forefront, paving the way for a future where AI seamlessly integrates with city governance. Iveda Philippines will emerge as a trailblazer in 2024, propelling the nation towards a more secure, efficient, and technologically-empowered future.
As Iveda continues to scale its global footprint, we affirm our position as a leader in the AI sector, leveraging groundbreaking technologies to create a smarter and safer world for all.”
To Management’s Knowledge Iveda Solutions (NASDAQ: IVDA) Is The Only Major Provider of Enterprise Class Real-Time Video Surveillance in The U.S.
Iveda Solutions, Inc. developed Sentir, a revolutionary Software as a Service video management platform, which enables companies such as telecom, cable, Internet, and other utility companies with subscribers already paying for monthly services, to offer cloud video surveillance services for additional recurring monthly revenue.
MegaSys, Iveda’s Taiwanese subsidiary, specializes in deploying video surveillance systems for airports, commercial buildings, government customers, data centers, shopping centers, hotels, banks, and Safe City initiatives in Taiwan and other neighboring countries. MegaSys integrates security surveillance products, software and services to provide integrated security solutions to the end user. Most of MegaSys’s revenues are derived from one-time sales, which differs from Iveda’s business model of on-going video hosting, remote video storage, and real-time surveillance revenues.
MegaSys does not own any proprietary technology or intellectual property other than certain trademarks in China and Taiwan used in its business. MegaSys serves as Iveda’s research and development arm, with in-house developers, as well as managing and directing its technology partner. MegaSys also manages relationships with manufacturers to find new devices to enable Iveda’s cloud video hosting services.
Historically, Iveda Solutions, Inc. has derived revenues from security systems integration, equipment sales and installation, conversion of analog cameras to digital, and per hour, per camera service fees from video hosting and real-time surveillance. Additional revenues are derived from extended video storage and extended maintenance contracts.
Iveda Solutions, Inc. has grown only through direct sales of equipment/installation and video surveillance services through its direct sales team. Since June 2012, Iveda has been developing its indirect sales channel using independent agents and security integrators. Iveda has been in active communication with telecommunications companies in Asia and Africa and expects to sign an agreement with them for reselling of Iveda’s cloud video hosting services.
Iveda Solutions, Inc. currently has a signed agreement with a Mexico-owned company based in the U.S. As the reseller channel matures, Iveda’s channel partners are expected to take over its equipment sales and installation functions, and help drive Iveda’s recurring service revenue.
After months of rigorous application and due diligence process, in April 2009, Iveda Solutions, Inc. was approved as a Qualified Anti-Terrorism Technology provider under a formal SAFETY Act Designation by the Department of Homeland Security (DHS). The designation gives the Company, its partners and customers certain liability protection.
Iveda Solutions Is Currently the Only Company, Offering Real-Time IP Video Hosting and Remote Surveillance Services with a SAFETY Act Designation
In September 2010, Iveda Solutions, Inc. acquired its first international customer.
The Company is now providing IvedaOnBoard, its in-vehicle live streaming video service, and remote video storage to a government agency in Mexico.
In April, 2011, Iveda completed the acquisition of MEGAsys Taiwan. MEGAsys designs and manufactures electronic security and surveillance products, software, and services. MEGAsys was founded in 1998 by a group of sales and research and development professionals from Taiwan Panasonic Company. Iveda leverages MEGAsys’ relationships with manufacturing and software companies in Asia, potentially reducing costs and improving services and capabilities. The acquisition also opens doors to the Asian market.
In October 2011, Iveda signed a strategic collaboration agreement with Telmex, U.S.A., a subsidiary of the Mexico-based Telmex, the 4th largest telecommunications company in the world.
Telmex has presence in the U.S., Latin America, Europe, and Africa. Iveda has developed a product, ideal for Telmex’ Mln’s of subscribers in the U.S. and Mexico.
In November 2012, Iveda Solutions, Inc. signed a cooperation agreement with Industrial Technology Research Institute (ITRI). ITRI is a research and development organization based in Taiwan. Iveda and ITRI have been co-developing cloud-video services. ITRI has given Iveda license to some of their patents being used in the development. Iveda will have exclusive rights to the products and services being co-developed.
Iveda Solutions Cloud Video Surveillance Services
Iveda Solutions, Inc. has multiple recurring revenue streams based on its cloud-video management platform, including video hosting, in-vehicle mobile video streaming, real-time remote surveillance services, and live streaming video mapping service, using a combination of Internet-enabled cameras, a secure IP network infrastructure utilizing robust data centers, and intervention specialists. Iveda’s services are all web-based and accessible through any Internet-accessible device (e.g., computer, smartphone, tablets).
Iveda Awarded $3.2M Contract for Confidential Application by Taiwanese Government Agency
PUBLISHED
FEB 26, 2024 9:00AM EST
Providing AI-powered technology, Iveda meets the growing demand for solutions in the region
MESA, Ariz.–(BUSINESS WIRE)– Iveda® (NASDAQ:IVDA), the global solution for cloud-based AI, today announced a signed contract with an undisclosed government agency worth approximately $3.2 million for a confidential application. This contract is in addition to the $2.7 million and $1.7 million announced in August 2022 and August 2023, respectively, to this same undisclosed government agency for different applications. Providing cutting-edge, AI-powered technology, the contract deployment has begun and is expected to be completed by 2026, delivering and deploying network equipment solutions to meet the growing demand for enhanced infrastructure. The execution will be overseen and managed by Iveda Taiwan.
“As safety and security remain a top priority for government organizations around the world, the need for AI-powered technology becomes paramount,” said David Ly, Iveda CEO and founder. “Through this contract, Iveda is dedicated to the continued improvement of security operations worldwide. Leveraging the power of AI, this contract positions Iveda Taiwan as a trusted partner in meeting the growing demand for cutting-edge AI solutions, keeping citizens, communities, and government personnel safe.”
“This achievement underscores Iveda Taiwan’s commitment to delivering comprehensive network equipment solutions to enhance AI-powered technology capabilities in the region,” added Ing-Hang Shiau, president of Iveda Taiwan. “As Iveda continues to expand its footprint in the global AI market, this contract reinforces our reputation for delivering high-quality products and services to clients around the world.”
This news follows closely behind additional global contract wins––including expansions in Egypt and deals in the Philippines and Vietnam––worth millions of dollars of revenues and gross profits to Iveda in 2024 and recurring revenue for years to come. With new cutting-edge smart city solutions to be announced throughout the year, Iveda remains dedicated to leveraging its expertise in AI-powered technology to provide customers around the world with solutions to keep citizens safe.
Iveda and VinaFore, Authorized AI Solutions Provider to the Vietnamese Government, Partner for Multi-Million Dollar AI Security and Safety Solutions Mandated Across Vietnam
PUBLISHED
FEB 22, 2024 9:00AM EST
In collaboration with the Vietnamese government, the organizations will join forces on design and technology specifications for smart city projects throughout the country
MESA, Ariz.–(BUSINESS WIRE)– Iveda® (NASDAQ:IVDA), the global solution for cloud-based AI, today announced a partnership with VinaFore Informatics and Telecommunication JSC to bolster transportation, telecom, and smart city solutions throughout Vietnam. After signing a memorandum of understanding (MOU) with the Vietnamese government in 2023, VinaFore selected Iveda to incorporate its leading AI capabilities into current infrastructure and will use IvedaAI to effectively improve upon existing solutions throughout the region. These projects are currently in the design phases and are anticipated to be multi-million-dollar undertakings for 2024 and over the course of the next several years.
“Last year was spent laying critical groundwork alongside VinaFore; now, 2024 is slated to be a year of massive growth and implementation for Iveda across Vietnam,” said David Ly, Iveda CEO and founder. “With use cases spanning traffic and transportation, manufacturing, and safety, Iveda’s powerful AI and virtual reality technology will help propel VinaFore and its partners into the fifth industrial revolution, bringing Vietnamese smart cities to life while dramatically increasing Iveda’s presence and market share throughout the region.”
According to MarketsandMarkets, the global intelligent transportation system market is projected to reach nearly $7B by 2028. Over the course of 2024, VinaFore will work with Iveda––in collaboration with additional in-country partners including CMC Corporation, Mobifone, and Hanoi Telecom––to establish a solid foundation for future AI technology deployments and smart city expansions in the transportation space and beyond. Projects include:
Information Technology Service (ITS) project with the Department of Transportation in Hanoi: IvedaAI’s Machine Vision technology––and its ability to classify and quantify vehicles and people, while identifying high-traffic time, space, and frequency, all in real time––will aid VinaFore in improving traffic congestion pains throughout the capital and surrounding areas.
Active project with the Vietnam Road Administration: VinaFore will be integrating IvedaAI to help manage the types of vehicles traveling throughout parts of the region at certain times of day to improve safety and traffic congestion. This project will stretch from Saigon to the Long An Province(approximately 75 kilometers) and is scheduled to kick off in Q2 of 2024.
Operational improvements to Vietnamese industrial parks: In collaboration with its partner network throughout the country, VinaFore will incorporate Iveda technology to increase operational efficiencies and safety improvements to over 600 industrial parks across Vietnam. With more than 100 AI features and applications already identified as immediately valuable to these industrial customers––including people and vehicle counting, face recognition, license plate recognition, fire and smoke detection, and intrusion detection––this project is slated to begin this year with integration and API work between providers and stakeholders already well underway.
Proof of concept project (POC) with a major printed circuit board (PCB) manufacturer: This POC will use Iveda’s newly released AI vision software vumastAR to conduct quality control inspections of products prior to final packaging. Iveda and VinaFore are currently working with the customer to actively train vumastAR’s customizable AI technology for a variety of automated inspection tasks. As a result of this POC, VinaFore will be showcasing IvedaAI and vumastAR at SaigonTex 2024, the largest textile and garment industry expo in the Association of Southeast Asian Nations. At the event, Iveda will demonstrate the technology’s capabilities to thousands of major manufacturers throughout the greater Southeast Asian region.
Partnership with the city of Da Nang: Known for being one of Vietnam’s most innovative and technologically advanced cities, Da Nang is well-equipped with telecommunication infrastructure and mature ITS projects. Over the course of 2024, Iveda will work to layer its AI capabilities into the city’s existing infrastructure, adding functional intelligence to the video cameras already in place throughout the city.
This news comes on the heels of major Iveda expansion and partnerships across the Philippines and Egypt. With VinaFore offices in San Francisco, Taipei, Hanoi, Saigon, Shanghai, Singapore, Jakarta, Myanmar, and Cambodia, this ongoing partnership is slated to propel Iveda’s growth and increase market expansion opportunities throughout 2024 and beyond.
From concerns spanning weather, economics, sustainability, population, and much more, our smart city solutions have the power to solve your regions' biggest challenges. $IVDAhttps://t.co/GmmEwgMtul
Iveda Expands Smart City Footprint Across Egypt; Opens Cairo Office and Strategic Demonstration Showcase
PUBLISHED
FEB 15, 2024 9:00AM EST
Six months after partnering with The Arab Organization for Industrialization, Iveda solidifies leadership in 5G, AI, and sustainable technologies throughout the region
MESA, Ariz.–(BUSINESS WIRE)– Iveda® (NASDAQ:IVDA), the global solution for cloud-based AI, today announced the opening of a new office in Cairo, Egypt as part of the organization’s work with The Arab Organization for Industrialization (AOI). Just six months after partnering with AOI, the showcase space––located inside the AOI government facility in Cairo––will serve as a demonstration room, putting Iveda’s smart city innovations and AI offerings on functional display, with the ability to demo to all interested parties. This announcement further solidifies the organization’s foothold as a leader in 5G, AI, and sustainable technologies throughout Egypt and the greater EMEA (Europe, Middle East, Africa) region.
Iveda’s smart city innovations and AI offerings on display include the Utilus Smart Pole with an average price to municipalities of $35,000 per pole, and city deployments are anticipated to range from 100 to 1,000 Utilus Smart Poles (or $3.5 million to $35 million) depending on the size of coverage required.
Iveda and AOI partnered in August of 2023 to support and scale smart city developments across Egypt and the wider EMEA region through the development of 13 smart cities. In support of the Egyptian government’s plans to introduce 38 new smart cities across the country by 2050, the two entities are marrying Iveda’s global IoT and AI technology and application expertise with AOI’s regional demand for innovation, equipping Egypt’s new administrative capital with the 5th generation smart city technology needed to make this goal a reality.
Egypt’s AI market is projected to reach $601.8 Million with an anticipated annual growth rate of 18.99%, resulting in a market volume of $2.03 Billion by 2030. This strategic office will dramatically improve speed-to-market of Iveda technologies by providing easier access to hands-on education, sales demonstrations, marketing opportunities, and firsthand proof-of-concept verification to those in the region. Major General Ashraf Hassan––who was appointed to Iveda’s Advisory Board in August 2023––will play a critical role in showcasing Iveda’s technologies, capabilities, and value to government and private enterprises across Egypt. Additionally, AOI will actively promote the value that local production of Iveda products is bringing to the area, in terms of both job and economic opportunities.
“Oftentimes, when it comes to new and advanced technologies––especially in the artificial intelligence and smart city realm––seeing is believing. That’s why we’re collaborating with AOI to make it easier for people in and around Egypt to visit and experience Iveda’s core technology firsthand,” said David Ly, CEO and founder of Iveda. “We’re eager to get our products into the hands of more organizations and government officials throughout the region, all while optimizing the decision-making process with potential customers and partners.”
Iveda has also been working with partners in South Africa, building up multi-million-dollar pipelines of opportunities. These clients are eager to witness Iveda’s offerings and the Cairo space will provide a convenient destination for the African market to experience the tech hands-on. Iveda products and technology to be displayed for live demonstration at the new Cairo location will include IvedaAI, Iveda Smart Drone, IvedaCare, and IvedaEMS through Cerebro. For more information, please visit iveda.com.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY IVDA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
EFSH Boasts $90Million in Revenue guidance, a Market Cap of under $10MM and only 735,730 shares in the float
1847 Announces $1.95 Million Repayment of Convertible Notes-$6.4 million of outstanding debt and liabilities have been eliminated over the past two weeks
Capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises or lower-middle market businesses with limited exit options despite the intrinsic value of their business.
Given this dynamic, 1847 Holdings (NYSE: EFSH) can consistently acquire businesses it views as “solid” for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems of those businesses in order to improve operations.
The end result? These improvements may lead to a sale or IPO of an operating subsidiary at higher valuations than the purchase price and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH’s ability to pay regular and special dividends to shareholders.
1847 seeks to invest in companies whose business models enable them to drive their own growth. We anticipate this will permit us to invest successfully, and develop deep expertise, in nine primary industries. Our experience and sector focus compounds our ability to evaluate and execute investment opportunities quickly, and add significant value post-closing.
1847 Holdings LLC (NYSE American:EFSH), was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue, and former Principal of Lazard Freres Strategic Realty Investors. 1847 Holdings’ investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises or lower-middle market businesses with limited exit options despite the intrinsic value of their business. Given this dynamic, 1847 Holdings can consistently acquire businesses it views as “solid” for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems of those businesses in order to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at higher valuations than the purchase price and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to 1847 Holdings’ ability to pay regular and special dividends to shareholders.
EFSH Competitive Advantages
▪ Robust Network ▪ National network of personal relationships with intermediaries, seasoned operating executives, entrepreneurs and managers
▪ Disciplined Deal Sourcing ▪ Leverages relationships with more than 3,000 qualified deal sources through regular calling, mail and email campaigns, industry events, etc.
▪ Differentiated Acquisition Capabilities in the Small Business Market ▪ Concentrated efforts on mature companies with sustainable value propositions, which can be supported by its resources and institutional expertise
▪ Value Proposition for Business Owners ▪ Employ a creative, flexible approach by tailoring each acquisition structure tommeet liquidity needs and qualitative objectives of the target
▪ Operating Partner ▪ Consistently work with a strong network of seasoned operating partners, former executives with extensive experience building, managing, and optimizing successful small business across a range of industries
▪ Small Business Market Experience ▪ Since 2000, the management team has collectively been presented with several thousand investment opportunities and actively worked with 30 small businesses on all facets of strategy, development and operations
EFSH FINANCIAL HIGHLIGHTS
Total revenue was $18.8M for Q3 2023 compared to $14.5M in Q3 2022, a29.8% year-over-year increase!
Gross profit was $8.0M in Q3 2023 compared to $4.9M in Q3 2022, a 64.9% year-over-year increase!
1847 Cabinets expanded their relationship with one of the nation’s leading home builders.
The company completed refinancing and upsizing of $15 million revolving credit facility for its subsidiary, ICU Eyewear
The company expanded its subsidiary, Wolo Manufacturing Corp, into India through a supply chain diversification program.
The company restructured promissory notes to non-dilutive debt instruments.
ACQUISITIONS
1847 Holdings (NYSE: EFSH) has acquired ICU, a leading designer of Over-the-Counter (OTC), non-prescription reading glasses, sunglasses, blue light-blocking eyewear, sun readers, and outdoor specialty sunglasses in February 2023. ICU was founded in 1956 and is headquartered in Hollister, California.
ICU is a recognized leader in reading eyewear and sunglasses, as well as select health and personal care items. ICU has 10 brands and a comprehensive and innovative product offering of over 3,000 SKUs across the reading glass, sunglass, and health & personal care segments.
ICU’s customer base consists of a broad range of national, regional, and specialty retailers comprising over 7,500 retail locations. ICU is the only OTC eyewear supplier in the U.S. to have meaningful penetration in all significant retail channels including grocery, specialty, office supply, pharmacy, and outdoor sports stores.
Acquisition Highlights:
Revenue in excess of $19M and $1.7M of adjusted EBTIDA in 2021.
ICU has developed a highly profitable and sustainable business model, with solid financials, positive EBITDA, and a gross margin of approximately 40%.
ICU has 10 brands and a comprehensive and innovative product offering of over 3,000 SKUs across the reading glass, sunglass, and health & personal care segments.
ICU’s customer base consists of a broad range of national, regional, and specialty retailers comprising over 7,500 retail locations.
The company’s eyewear line has earned the title of #1 provider of OTC eyewear at Target.
Kyle’s Custom Wood Shop, Inc.: Headquartered in Boise, ID, the company believes strong housing demand in the region is driven by out-of-state immigration into Idaho. Current operations are focused primarily in the Boise area, providing opportunities to capitalize on high-growth adjacent regions. In addition to regional expansion, EFSH plans to expand capacity by increasing the network of builders, participating in new bids, and investing in facilities and labor resources. Product line expansion and broadening sales channels to include multifamily housing remodels, and DIY segments could further accelerate growth.
Financial Highlights:
Revenues from the construction segment (incl. Kyle’s) increased by $21,830,922, or 523.6%, to $26,000,227 for the nine months ended September 30, 2022 from $4,169,305 for the nine months ended September 30, 2021.
Cost of sales for the construction segment increased by $13,555,821, or 594.6%, to $15,835,830 for the nine months ended September 30, 2022 from $2,280,009 for the nine months ended September 30, 2021.
Gross profit was $10,164,397 and $1,889,296 for the nine months ended September 30, 2022 and 2021, respectively.
WOLO Manufacturing Corp.: A leader in horn technology (electric, air, truck marine, electronic specialty, air & backup alarms) and vehicle emergency warning lights offering the highest quality and the largest selection for cars, trucks, and industrial equipment. Wolo has supplied innovative automotive products: horns, emergency warning lights, security, and lighting, to the automotive aftermarket for more than 45 years.
The company sells its products to big-box national retail chains, through specialty and industrial distributors, as well as online/mail order retailers and OEMs. With a stellar reputation for innovative design, its current product line consists of over 455 products, including 54 patented products, as well as over 90 exclusive trademarks.
Financial Highlights:
Revenues from the automotive supplies segment increased by $833,742, or 20.9% to $5,114,755 for the nine months ended September 30th, 2022 from $4,231.013 for the nine months ended September 30th, 2021.
Cost of sales for the automotive supplies segment increased by $369,368, or 13.9%, to $3,028,040 for the nine months ended September 30th, 2022 from $2,658.672 for the nine months ended September 30, 2021.
Gross profit was $2,086,715 and $1,572,341 for the nine months ended September 30, 2022 and 2021, respectively.
In October 2021, 1847 acquired High Mountain Door & Trim, Inc. & Innovative Cabinets & Design for an aggregate purchase price of approximately $15.4 million
Brief Overview
▪ High Mountain specializes in all aspects of finished carpentry products and services, including doors, door frames, base boards, crown molding, cabinetry, bathroom sinks and cabinets, bookcases, built-in closets, fireplace mantles, etc., working primarily with large homebuilders of single-family homes and commercial and multi- family developers
▪ Sierra Homes d/b/a Innovative Cabinets & Design specializes in custom cabinetry and countertops for a client base consisting of single-family homeowners, builders of multi-family homes, as well as commercial clients
Financial Highlights
▪ Revenues from the construction segment increased by $1,182,633, or 11.8%, to $11,230,579 for the three months ended September 30, 2023, from $10,047,946 for the three months ended September 30, 2022. The increase in revenues was primarily attributed to an increase in new multi-family projects and an increase in the average customer contract value.
▪ Cost of revenues for the construction segment decreased by $1,072,127, or 16.4%, to $5,472,716 for the three months ended September 30, 2023, from $6,544,843 for the three months ended September 30, 2022.
1847 Announces $1.95 Million Repayment of Convertible Notes
PUBLISHED
FEB 23, 2024 10:28AM EST
$6.4 million of outstanding debt and liabilities have been eliminated over the past week; further strengthening the Company’s balance sheet
New York, New York–(Newsfile Corp. – February 23, 2024) – 1847 Holdings LLC(NYSE American: EFSH) (“1847” or the “Company”), a unique holding company that combines the attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, today announced that it has successfully paid off $1.95 million in debt, following its recent public offering.
Mr. Ellery W. Roberts, CEO of 1847, commented, “We are pleased to announce the successful repayment of $1.95 million of convertible notes. By eliminating these convertible notes, we are enhancing our balance sheet and removing potential equity overhang. As part of our strategic balance sheet optimization initiative, over the past week, we have been able to eliminate $6.4 million of outstanding debt and liabilities. This transformative initiative reflects our commitment to transparency, clarity, and creating shareholder value. By restructuring our balance sheet, we are fortifying our financial foundation and better positioning our platform for growth and success. Through this enhanced structure, we can optimize capital allocation and unlock new opportunities for growth and value creation in 2024.”
1847 Reports 29.8% Increase in Revenue to $18.8 Million for Q3 2023
PUBLISHED
NOV 14, 2023 4:05PM EST
Gross profit increases 64.9% compared to the same period last year
NEW YORK, NY / ACCESSWIRE / November 14, 2023 /1847 Holdings LLC(“1847” or the “Company”) (NYSE American:EFSH), a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, today provided a business update and reported financial results for the three months ended September 30, 2023.
Q3 2023 Highlights and Subsequent Events
Total revenue was $18.8M for Q3 2023 compared to $14.5M in Q3 2022, a 29.8% year-over-year increase
Gross profit was $8.0M in Q3 2023 compared to $4.9M in Q3 2022, a 64.9% year-over-year increase
1847 Cabinets expanded relationship with one of the nation’s leading home builders
Regained compliance with NYSE American continued listing standards
Completed refinancing and upsizing of $15 million revolving credit facility for its subsidiary, ICU Eyewear
Expanded its subsidiary, Wolo Manufacturing Corp, into India through supply chain diversification program
Restructured promissory notes to non-dilutive debt instruments
Mr. Ellery W. Roberts, CEO of 1847 Holdings, commented, “I am pleased to report that revenues for the third quarter of 2023 increased by 29.8% and our gross profit increased 64.9% over the same period last year. We attribute this performance to the strength of our platform and our ability to support the growth of our portfolio companies, while at the same time improving their profitability. During the quarter, we successfully restructured convertible notes to eliminate the potential equity dilution, and recently Egan-Jones affirmed their BB+ rating on our senior credit facility, which further illustrates the strength of our balance sheet. Importantly, our cash flow continues to improve and based on our current trajectory, we expect to achieve over 50% revenue growth in 2023. Heading into 2024, we expect to continue our strong revenue growth, which should significantly enhance our profitability as we leverage our fixed costs and benefit from economies of scale. We also believe that the intrinsic value of the business has not been recognized by the public market, and, as a result, we continue to explore a variety of strategic options which could include spinoffs of subsidiaries or privatization of the Company to maximize value for our shareholders.”
Q3 2023 Financial Highlights
Total revenues were $18,777,921 for the three months ended September 30, 2023, as compared to $14,472,361 for the three months ended September 30, 2022.
Revenues from the retail and appliances segment decreased by $513,697, or 17.5%, to $2,421,008 for the three months ended September 30, 2023, from $2,934,705 for the three months ended September 30, 2022. The decline in revenues was primarily attributed to ongoing supply chain delays and decreased customer demand.
Revenues for the retail and eyewear segment were $4,243,254 for the three months ended September 30, 2023.
Revenues from the construction segment increased by $1,182,633, or 11.8%, to $11,230,579 for the three months ended September 30, 2023, from $10,047,946 for the three months ended September 30, 2022. The increase in revenues was primarily attributed to an increase in new multi-family projects and an increase in the average customer contract value.
Revenues from the automotive supplies segment decreased by $606,630, or 40.7%, to $883,080 for the three months ended September 30, 2023, from $1,489,710 for the three months ended September 30, 2022. The decline in revenues was primarily attributed to ongoing supply chain delays with manufacturers and decreased customer demand.
Total cost of revenues was $10,737,174 for the three months ended September 30, 2023, as compared to $9,596,387 for the three months ended September 30, 2022.
Cost of revenues for the retail and appliances segment decreased by $207,941, or 9.5%, to $1,976,031 for the three months ended September 30, 2023, from $2,183,972 for the three months ended September 30, 2022.
Cost of revenues for the retail and eyewear segment was $2,662,586, or 62.7% of retail and eyewear revenues, for the three months ended September 30, 2023.
Cost of revenues for the construction segment decreased by $1,072,127, or 16.4%, to $5,472,716 for the three months ended September 30, 2023, from $6,544,843 for the three months ended September 30, 2022.
Cost of revenues for the automotive supplies segment decreased by $241,731, or 27.9%, to $625,841 for the three months ended September 30, 2023, from $867,572 for the three months ended September 30, 2022.
Total general and administrative expenses were $4,195,261 for the three months ended September 30, 2023, as compared to $2,505,571 for the three months ended September 30, 2022.
Net loss from continuing operations was $5,859,072 for the three months ended September 30, 2023, as compared to a net loss of $4,472,622 for the three months ended September 30, 2022. Such change was primarily due to interest expense of $5,074,169 and other expense of $187,200. Excluding this, the Company’s net loss from continuing operations for the three months ended September 30, 2023 would have been $597,703.
Nine Month 2023 Financial Highlights
Total revenues were $53,572,198 for the nine months ended September 30, 2023, as compared to $39,437,482 for the nine months ended September 30, 2022.
Revenues from the retail and appliances segment decreased by $1,434,911, or 17.2%, to $6,887,589 for the nine months ended September 30, 2023, from $8,322,500 for the nine months ended September 30, 2022.
Revenues for the retail and eyewear segment were $11,530,027 for the period from February 9, 2023 (date of acquisition) to September 30, 2023.
Revenues from the construction segment increased by $5,646,972, or 21.7%, to $31,647,199 for the nine months ended September 30, 2023, from $26,000,227 for the nine months ended September 30, 2022.
Revenues from the automotive supplies segment decreased by $1,607,372, or 31.4%, to $3,507,383 for the nine months ended September 30, 2023 from $5,114,755 for the nine months ended September 30, 2022.
Total cost of revenues was $32,774,377 for the nine months ended September 30, 2023, as compared to $25,109,863 for the nine months ended September 30, 2022.
Cost of revenues for the retail and appliances segment decreased by $784,127, or 12.6%, to $5,461,866 for the nine months ended September 30, 2023, from $6,245,993 for the nine months ended September 30, 2022.
Cost of revenues for the retail and eyewear segment was $7,102,908, or 61.6% of retail and eyewear revenues, for the period from February 9, 2023(date of acquisition) to September 30, 2023.
Cost of revenues for the construction segment increased by $2,212,564, or 14.0%, to $18,048,394 for the nine months ended September 30, 2023, from $15,835,830 for the nine months ended September 30, 2022.
Cost of revenues for the automotive supplies segment decreased by $866,831, or 28.6%, to $2,161,209 for the nine months ended September 30, 2023, from $3,028,040 for the nine months ended September 30, 2022.
Total general and administrative expenses were $10,715,638 for the nine months ended September 30, 2023, as compared to $6,737,782 for the nine months ended September 30, 2022.
Net loss from continuing operations was $8,781,627 for the nine months ended September 30, 2023, as compared to a net loss of $5,547,498 for the nine months ended September 30, 2022. Such change was primarily due to interest expense of $9,747,299 and other expense of $135,232. Excluding this, the Company’s net income from continuing operations for the nine months ended September 30, 2023 would have been $1,100,904.
1847 Secures $750,000 Credit Facility for its Wolo Manufacturing Subsidiary
PUBLISHED
JAN 24, 2024 9:00AM EST
NEW YORK, NY / ACCESSWIRE / January 24, 2024 / 1847 Holdings LLC (“1847” or the “Company”) (NYSE American:EFSH), a unique holding company that combines the attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, today announced that it has secured a $750,000 credit facility for its Wolo Manufacturing Corp. (“Wolo”) subsidiary.
Wolo is a leading manufacturer and distributor of vehicle horns and safety products (electric, air, truck, marine, motorcycle and industrial equipment), and offers vehicle emergency and safety warning lights for cars, trucks, industrial equipment and emergency vehicles.
Mr. Ellery W. Roberts, CEO of 1847, commented, “We are pleased to have secured this credit facility for Wolo, a strategic move that empowers Wolo with working capital to fulfill orders due to strong customer demand. Furthermore, this facility strengthens Wolo’s liquidity and increases its financial flexibility, enabling it to grow its business without any equity dilution at either the 1847 or subsidiary level. With this enhanced credit capacity, combined with growing customer demand and easing of supply chain pressure, Wolo has the potential to increase its sales by 50% to 70% year-over-year in 2024.”
Additional details Wolo’s credit facility will be available upon the filing of a Current Report on Form 8-K, which will be filed with the Securities and Exchange Commission and available on the Company’s website once filed.
The company was founded by CEO Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue, and Principal of Lazard Freres Strategic Realty Investors.
Ellery W. Roberts leading the reins has helped elevate EFSH to an NYSE listing and his expertise could soon lead the company to much greater heights!
Mr. Roberts has 20+ years of private equity investing experience; directly involved in $3+ billion transactions.
He formed RW Capital Partners LLC, an investment manager approved by the Investment Committee of the U.S. Small Business Administration in 2010 to raise and manage a Small Business Investment Company.
He previously was a Managing Director of Parallel Investment Partners LP, responsible for ~$400 million in invested capital across two funds.
He served as a Principal at Lazard Freres & Co. working in their Real Estate Principal Investment Area, where he was a senior team member involved in the investment of over $2.4 billion of capital.
Mr. Roberts worked at Colony Capital, Inc., a $625 million private equity fund.
He has experience as an Investment Banker in the Corporate Finance division of Smith Barne.
“I’m pleased to report revenues increased by 27.6% to $15.4 million and we achieved net income of $1.0 million for the first quarter of 2023. At the same time, our gross profit increased 35.0% over the same period last year. These results are further validation of the strength of our platform and our ability to acquire undervalued, cash flow positive, lower-middle market businesses at attractive valuations with minimum dilution to shareholders. Importantly, we are reaffirming our prior guidance of revenue in excess of $90 million in 2023.”
CEO Ellery W. Roberts
Vernice L. Howard – Chief Financial Officer
Ms. Howard has served as Chief Financial Officer since September 2021. She has over 30 years of experience in the fields of finance and accounting. Prior to joining us, she worked for Independent Electrical Contractors, Inc. and its affiliates for over eleven years as Chief Financial Officer, where she was responsible for providing leadership to the organization in the areas of finance, human resources and general facilities administration, in addition to setting policies, procedures, strategies, practices and overseeing the organization’s assets. The foundation of Ms. Howard’s accounting and finance experience began with public accounting for several years gaining experience in tax and auditing in the entertainment and nonprofit sectors as Chief Financial Officer for The Cronkite Ward Company, a television production company, and Director of Finance for Community Action Group (CAG), a nonprofit organization. Before her work with Independent Electrical Contractors, Inc., Ms. Howard’s professional background established an emphasis in forensic accounting. Ms. Howard is a Founding Member of Chief, which is a DC based vetted network of C-level or rising VP’s supporting and connecting exceptional women. Ms. Howard holds a Master of Business Administration in Finance from Trinity Washington University Graduate School of Business Management and Bachelor of Science in Accounting from Duquesne University.
Glyn C. Milburn – Vice President of Operations
Mr. Milburn joined 1847 in February 2023 after serving as a member of the company’s board of directors since August 2022. Mr. Milburn brings diverse operational and strategic expertise across multiple sectors, including commercial finance, labor negotiations, and operations management.
Before joining 1847, Mr. Milburn served as a Director at Ygrene Energy Fund, a consumer finance company based in California. Mr. Milburn also served as Partner at Jimmy Blackman & Associates, a full-service government and public affairs firm, where he was responsible for business strategy, client management, communications, and campaign management for a client portfolio comprised of large public safety labor unions, banking/finance companies, and hotel operators across the state of California. Mr. Milburn has also served as a special assistant in the City of Los Angeles, where he held two positions, one in the office of Los Angeles Mayor Eric Garcetti’s Office of Economic Development and another in the office of Los Angeles City Council. Previously, Mr. Milburn served as Executive Vice President of Texas AF2 Holdings, managing a portfolio of sports franchises handling their operations, compliance, and strategic planning.
Mr. Milburn co-founded Provident Investment Advisors LLC, a special investment vehicle for energy, technology, and healthcare ventures, where he served as a managing member. Mr. Milburn also serves on the board of directors ofPolished.comInc. Mr. Milburn holds a B.A. degree in Public Policy from Stanford University and an M.B.A. from the Kelley School of Business at Indiana University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSANDUSDBY INTERACTIVE OFFERS LLC FOR A ONE DAY EFSH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Total revenue was $12.9 million for the nine months of 2023, an increase of 93% compared to total revenue of $6.7 million in the prior year period, driven by an increase in sales in both Service and Product revenue which were significantly positively impacted by acquisitions.
Service revenue for the nine months of 2023 increased 88% to $9.2 million primarily driven by acquisitions of animal hospitals and clinics accumulated since the prior period.
Product revenue of $3.7 million increased 110% compared to the prior year period driven primarily by acquisitions of animal hospitals and clinics in 2023.
The APPA National Pet Owners Survey revealed that 66% of U.S.households own a pet. This translates to about 86.9 million households with pets
There is another company that we want to bring to your attention immediately.
The number of U.S. homes with pets has been trending upward for decades, with more than 5 million more pets in the U.S. than before the pandemic. Beyond the pandemic-driven boom, the trends continue, driven by changing social dynamics as well as technological advancements. According to Morgan Stanley, the pet services industry is set to grow at a compound annual growth rate (CAGR) of 8% over 2022-2030, reaching a projected total of $277 billion.
Average annual household spending per pet could grow from $980 in 2020 to $1,292 by 2025 and expand further to $1,909 by 2030, according to Morgan Stanley. This growth would be distributed across various categories, including pet food, veterinary care and a handful of other services. Additionally, there is a booming set of sub-sectors like dog walking, pet-sitting, grooming and training, underscoring the scale and scope of the industry’s growth. Amidst this broad expansion, this upward trend in sales is estimated by some to be a full 50% higher in 2023 at $143.6 billion.
Pull up IVP Immediately.
The U.S. pet industry generated $103B in 2020. In 2017 there were 28,000+ pet hospitals in the U.S.
Inspire is an owner of general practice veterinary clinics in the United States. Inspire acquires practices, and, in many cases real estate, and then works with teams on a long- term basis to improve and maintain hospital operations, grow revenues and maximize earnings. As the Company expands, it is adding new services hospitals, including mixed animal facilities, critical and emergency care, and other specialty services such as equine, in one location.
Inspire Veterinary Partners (NASDAQ: IVP): Empowering Veterinary Professionals Through Its Employee-Oriented Ownership Model
VIRGINIA BEACH, VA / ACCESSWIRE / January 25, 2024 /Inspire Veterinary Partners Inc. (NASDAQ:IVP) introduces a distinctive approach to veterinary practice ownership that is markedly different from traditional investment models. This approach, diverging from the top-down that uses short-term strategies typical in private equity, emphasizes engaged ownership and a commitment to the well-being of both pets and veterinary professionals.
Transitioning Ownership With Inspire
Inspire provides a unique pathway for veterinary practice owners considering a transition. Unlike the traditional top-down models, where changes are often dictated by far-removed executives, Inspire’s process involves a collaborative approach to understanding and enhancing the unique qualities of a practice. This method respects the value of the hospital while empowering employees to engage in self-directed change, ensuring that veterinary practices remain integral parts of their communities and firmly in the hands of those most qualified to run their respective practices: the employees. The Inspire model is also designed around long-term benefits for team members and clients versus the shorter timeframes dictated by ownership structures within Private Equity owned practices.
Employee-Centric Ownership And Benefits
Inspire’s model is built on employee and shareholder ownership, led by experienced veterinary professionals. This structure aims to facilitate significant employee input in decision-making and fosters a culture of resilience, trust and respect. Comprehensive pay, benefits and customizable compensation packages are emphasized right from the beginning of a partnership, aimed at meeting individual needs and aspirations while contributing to a more satisfied and motivated workforce. With equity offerings planned for a large portion of the IVP workforce, the company is decidedly different from other consolidators in the pet care space which typically do not offer ownership, or when offered, the equity is only available to a select few.
Empowerment And Community Engagement
The Inspire organization is equally committed to veterinary care as it is personal development and mentorship, empowering veterinary professionals to positively impact their communities. Inspire’s philosophy extends beyond financial interests, offering a sense of ownership and pride in their work, partners and communities. The future of veterinary care with Inspire is envisioned as one where practices are more than businesses – they are vital community members providing high-quality care to pets and peace of mind to pet owners through a bottom-up employee-driven business model. With experienced veterinary professionals in every department at Inspire and veterinarians in many support and leadership functions, the company prides itself on ensuring decisions are made with the long-term interest of the workforce, veterinary industry and shareholders alike.
Joining Inspire Inspire Veterinary Partners
For potential sellers seeking an acquisition partner for their hospital, joining Inspire involves an in-depth and personalized process. Meetings with Business Development at IVP lead to further conversation and hospital visits with operations and medical leadership and culminate in a visit with CEO Kimball Carr. Each meeting includes discussions about compensation and community goals and the entire. The process aims to foster trust and collaboration from the start, encompassing in-person interactions and town hall Q&A sessions.
Redefining Veterinary Care In The Private Equity Era
By prioritizing employee ownership and involvement alongside comprehensive compensation and benefits packages, Inspire Veterinary Partners aims to align the interests of veterinary professionals, pet owners and their pets. This approach challenges the conventional norms of veterinary practice ownership and offers an alternative model focused on community engagement and personal development. While the long-term impacts of such a model in the broader veterinary industry are yet to be fully realized, Inspire’s strategy presents a novel perspective for those considering the evolving landscape of veterinary healthcare.
THE NEAR FUTURE
The 5-year plan includes a 10 location per year run rate for acquisitions and a public event within that timeframe which allows Inspire to share equity with all associates working in its locations.
DIFFERENTIATORS
Key relationships from the acquisition process through operations and the unique position of a publicly-traded veterinary services organization, provide us advantages in growth capability,
WHAT IS INSPIRE, WHAT IS THE 5 YEAR PLAN?
Key relationships from the acquisition process through operations and the unique position of a publicly-traded veterinary services organization, provide us advantages in growth capability,befficiency and employee retention.
Inspire Veterinary Partners Reports Third Quarter 2023 Financial Results
VIRGINIA BEACH, VA / ACCESSWIRE / November 14, 2023 / Inspire Veterinary Partners, Inc.(NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today reported financial results for its third quarter and nine months ended September 30, 2023.
“We are pleased to report strong third quarter 2023 results as a newly public company with total revenue growing 41 percent year-over-year,” said Kimball Carr, Chairman, President & Chief Executive Officer of Inspire. “The positive momentum in our business has continued through the third quarter making us optimistic about our overall growth prospects in 2023. Looking forward, we believe there is significant opportunity ahead of us in the large, growing, and unconsolidated pet care market.”
Mr. Carr added, “With our successful initial public offering behind us, we are very excited about the opportunity to accelerate the pace of our animal hospital acquisition program. We recently completed the acquisition of our first animal hospital in Pennsylvania, Valley Veterinary Service, whose 2022 gross revenues exceeded $1.7 million.Our team is focused on building a robust pipeline of acquisition targets. With 14 hospitals in 10 states, we believe there is a lot of growth potential ahead of us both organically and through acquisition. We are excited to execute our growth strategy and deliver enhanced value for our shareholders.”
Third Quarter 2023
Total revenue was $4.1 million for the third quarter of 2023, an increase of 42% compared to total revenue of $2.9 million in the prior year period, driven by an increase in sales in both Service and Product revenue which were significantly positively impacted by acquisitions. Service revenue for the third quarter of 2023 increased 30% to $2.9 million, driven primarily by three new animal hospitals and clinics acquired in 2023. Product revenue of $1.2 million increased 76% compared to the prior year period also driven primarily by the acquisition of additional animal hospitals and clinics in 2023.
General and administrative expenses increased $1.8 million or 103%, to $3.6 million for the three months ended September 30, 2023 compared to $1.8 million for the three months ended September 30, 2022. The increase was primarily due to the expenses generated by the Company’s acquired animal hospitals and clinics, the start-up and organizational expenses associated with the acquisitions and the costs associated with the Company’s initial public offering and listing on the Nasdaq Capital Market.
Net loss was $7.9 million for the third quarter of 2023 compared to net loss of $1.4 million for the prior year period. The increase in net loss was primarily attributable to the additional operating expenses, the non-cash beneficial conversion feature of $4.1 million on the convertible debenture and series A preferred stock recognized upon the completion of the IPO and the acquisition costs associated with the Company’s recently acquired animal hospitals and clinics. The Company also incurred additional costs associated with the initial public offering that closed on August 31, 2023.
First Nine Months of 2023
Total revenue was $12.9 million for the nine months of 2023, an increase of 93% compared to total revenue of $6.7 million in the prior year period, driven by an increase in sales in both Service and Product revenue which were significantly positively impacted by acquisitions. Service revenue for the nine months of 2023 increased 88% to $9.2 million primarily driven by acquisitions of animal hospitals and clinics accumulated since the prior period. Product revenue of $3.7 million increased 110% compared to the prior year period driven primarily by acquisitions of animal hospitals and clinics in 2023.
General and administrative expenses were $7.2 million for the first nine months of 2023 compared to $3.7 million in the prior year period. The increase was primarily due to the expenses generated by the Company’s animal hospitals and clinics acquired, the start-up and organizational expenses associated with acquisitions and the costs associated with the Company’s initial public offering and Nasdaq listing.
Net loss was $10.6 million for the first nine months of 2023 compared to a net loss of $3.0 million for the prior year period. The increase in net loss was primarily attributable to the additional operating expenses, the non-cash beneficial conversion feature of $4.1 million on the convertible debenture and series A preferred stock recognized upon the completion of the IPO and the acquisition costs associated with the Company’s recently acquired animal hospitals and clinics. The Company also incurred additional costs associated with its initial public offering.
Balance Sheet
As of September 30, 2023, the Company had cash and cash equivalents of approximately $1.9 million.
About Inspire Veterinary Partners, Inc.
Inspire Veterinary Partners is an owner/operator of veterinary hospitals in the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.
Inspire Veterinary Partners Announces Opening of Newly Relocated and Expanded Family Pet Care Animal Hospital in Sugarland, Texas
New hospital design represents model for future upgrades across the IVP platform
State-of-the-art facility has been designed to elevate service to customers while creating an efficient and attractive workplace environment for employees
VIRGINIA BEACH, VA / ACCESSWIRE / January 3, 2024 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today announced the opening of a its Sugarland, Texas animal hospital, in a new location and larger facility that incorporates state-of-the art design to better serve its customer and support its staff.
Rendering of IVP’s New and Expanded Sugarland, TX Animal Hospital
Opening in January 2024, Inspire is excited to make it possible for more Sugarland Texas area pet lovers to provide veterinary care for their animals at its newly relocated and expanded local hospital. Purpose built around the needs of IVP’s care team and clients, this modern, customized facility incorporates the veterinary teams’ guidance into the design, materials, floor plan and tools deemed necessary to provide world class care for pets. Family Pet Care in Sugarland also represents the model for future newly built practices as the Company strategically expands existing clinics to optimize pet care in the communities it serves.
“From initial concept through construction. this hospital has been built with the needs of our team and clients in mind,” said Dr. Alexandra Quarti, Vice President of Medical Operations of Inspire. “The design makes this hospital a great place to work with every modern tool necessary for high quality care while providing comfort and efficiency for our team.”
Inspire collaborated with its facilities team at Synergy PMC led by John Grimes and architectural and design experts Nour Architecture, to create a model hospital that it believes can be replicated at existing or newly acquired facilities. “This location was months in the designing and building, providing our Sugarland area team a best-in-class hospital from which to care for pets, with a design scheme that can be used across our entire platform,” stated Kimball Carr, Chairman, President & Chief Executive Officer of Inspire. “We believe Family Pet Care of Sugarland Texas will be the first of more to come for Inspire.”
Inspire Veterinary Partners Announces Acquisition of Valley Veterinary Service Animal Hospital
Latest acquisition brings the total number of Inspire locations to 14.
Expansion into a new state, Pennsylvania.
Pipeline of attractive potential acquisitions of animal hospitals remains active.
VIRGINIA BEACH, VA / ACCESSWIRE / November 8, 2023 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today announced that it has completed the acquisition of Valley Veterinary Service, Inc. animal hospital located in Pennsylvania, Inspire’s first entry in that state.
Valley Veterinary Service’s 2022 gross revenues were in excess of $1.7 million. As part of the transaction, Inspire acquired certain real estate assets related to Valley Veterinary hospital.
Kimball Carr, Chairman, President & Chief Executive Officer of Inspire, stated, “We are very excited to enter Pennsylvania and to collaborate with this remarkably committed and talented team who have been serving their community for years. The Valley team is expected to continue to operate the hospital and provide the same incredible care and service they have to so many clients and pets, while IVP leverages our expertise and infrastructure to enable the team at Valley to continue to be their best. Inspire looks forward to future nationwide growth opportunities.”
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY IVP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We are back with another exciting profile for you to research for tomorrow’s session.
Our Last one exploded 38% under 2 hours into the session like a rocket ship.
It opened at 1.37 and before 11:30 this one hit 1.90 on strong interest.
Our next one operates in a massive sector.
This is a company that uplisted to the Nasdaq back in August…….. not an easy task to accomplish.
Pull up FMST immediately.
GLOBAL LITHIUM-ION BATTERY MARKET SET TO SURGE OVER 295% BY 2032 (4)
Image Source (4)
The global lithium-ion battery market is on the brink of a monumental surge, poised to catapult over 295% to surpass a staggering $387 billion by 2032. This forecast underscores the relentless momentum driving the lithium-ion battery industry, propelled by a myriad of factors reshaping the energy landscape worldwide. (4)
Among regions, North America stands out as a beacon of rapid development within the lithium-ion battery market. Spearheaded by the United States, North America dominates this sector, fueled by a confluence of factors amplifying demand. The surge in automobile and electric vehicle sales across the region, coupled with the rising need for lithium-ion batteries in mobile phones, serves as pivotal catalysts propelling market expansion and development in North America. (4)
Unveiling Growth Factors
Image Source (12)
The prevalence of lithium-ion batteries in electronics and automobiles owes to their unparalleled efficiency and effectiveness. Their rechargeable nature adds to their allure, contributing significantly to their widespread adoption. (4)
The burgeoning electric vehicle market stands as a key driver fueling the global lithium-ion battery market’s growth trajectory over the projected period.(4)
With higher energy density and prolonged shelf life, lithium-ion batteries seamlessly integrate into vehicles and automobiles, amplifying their appeal. (4)
A crucial impetus behind the market’s expansion is the escalating consumer spending on consumer electronics. (4)
Moreover, the burgeoning adoption of electric vehicles, driven by the escalating costs of fossil fuels and gasoline, amplifies demand for lithium-ion batteries on a monumental scale, further augmenting market growth.(4)
The expanding renewable energy sector also emerges as a pivotal factor bolstering the lithium-ion battery market’s expansion. (4)
Government investments in energy and infrastructural projects amplify this growth, creating a conducive environment for market development. (4)
Collaborations between major market players and government agencies further amplify growth prospects, fostering an environment ripe for market expansion.(4)
In this dynamic landscape, Foremost Lithium Resource & Technology (Nasdaq: FMST) emerges as one company to keep a close eye on, especially since Zacks Small-Cap Research analyst Steven Ralston, CFA recently set a target of $6.20 for the company. (2)
This target suggests over 250% potential upside from Foremost Lithium’s 52-week low of $1.77 set on 10/25/2023 and over 113% potential upside from its recent opening of $2.90 on Monday, 2/12/2024. (2)(3)
Image Source (2)
Positioned strategically to capitalize on the burgeoning lithium-ion battery market, Foremost Lithium Resource & Technology (Nasdaq: FMST) stands poised for significant growth.
With a focus on innovation and sustainability, Foremost Lithium Resource & Technology (Nasdaq: FMST) positions itself as a hard-rock exploration company strategically poised to capitalize on the global “electrification revolution.” (5)
Committed to becoming a premier supplier of North America’s lithium feedstock, Foremost Lithium Resource & Technology (Nasdaq: FMST) directs its efforts towards exploration and growth on its four core Lithium Lane Projects in Snow Lake, Manitoba, as well as its Lac Simard South Property in Quebec. Additionally, the company holds the Winston Gold/Silver Property in New Mexico, USA. (5)
Amidst the world’s transition towards decarbonization, Foremost Lithium Resource & Technology (Nasdaq: FMST) stands ready to thrive in the industry’s unprecedented growth trajectory. (5)
With a robust presence in key lithium-rich regions, the company is well-equipped to navigate and seize the abundant opportunities that lie ahead as the global lithium-ion battery market surges to unprecedented heights. (5)
Keep reading to see why Foremost Lithium Resource & Technology (Nasdaq: FMST) needs to be at the top of your watchlist…
WHY FOREMOST LITHIUM RESOURCE & TECHNOLOGY (NASDAQ: FMST) NEEDS TO BE ON YOUR WATCHLIST
Analyst Coverage: With Zacks Small-Cap Research analyst Steven Ralston, CFA, setting a target of $6.20 for the company, Foremost Lithium Resource & Technology (Nasdaq: FMST) has garnered significant attention in the market. This target suggests over 250% potential upside from the company’s 52-week low of $1.77, set on 10/25/2023, and over 113%potential upside from its recent opening of $2.90 on Monday, 2/12/2024. (2)(3)
Low Float Situation: Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. That limited supply can cause dramatic price swings if demand changes quickly. (7) As of 2/12/2024, Foremost Lithium Resource & Technology (Nasdaq: FMST) has less than 4.5M shares available in its float according to Finviz.com. (6)
Clean Energy Revolution: Positioned strategically to contribute significantly to the clean energy future, Foremost Lithium Resource & Technology (Nasdaq: FMST) is focused on extracting lithium oxide, a crucial component in lithium-based batteries powering the electric vehicle (EV) revolution. The company stands at the forefront of facilitating the transition towards decarbonization. (8) The global lithium-ion battery market is on the brink of a monumental surge, poised to catapult over 295% to surpass a staggering $387 billion by 2032.(4)
Extensive Land Holdings: Operating several strategically located properties covering over 55,1180 acres in Snow Lake, Manitoba, and Quebec, Foremost Lithium is well-positioned to meet North America’s growing lithium demand. This extensive landholding underscores the company’s potential to supply crucial resources for the rapidly expanding EV and battery storage markets. (8)
Streamlined Exploration Processes:The recent issuance of a multi-year work permit by the Manitoba government’s Mining Permit Office until April 30, 2026, is a significant catalyst for Foremost Lithium. This permit streamlines exploration processes at the Zoro Lithium Project, enabling more efficient, cost-effective, and safer exploration strategies. (8)
Strategic Partnerships and Support:Foremost Lithium’s partnership with local companies for drilling, air support, core storage, and technical support ensures comprehensive operational backing for its exploration programs. Additionally, the company’s receipt of a $300,000 grant from the Manitoba Mineral Development Fund (MMDF) underscores external confidence in its potential and contribution to sustainable development. (8)
Aggressive Resource-Building Initiatives: The company’s ambitious winter drilling program at the Zoro Lithium Property, targeting Dyke 1 and previously drilled lithium spodumene dykes, reflects its commitment to expanding resource-building efforts. Aligning with North America’s escalating demand for EVs and clean energy solutions, this initiative positions Foremost Lithium as a pioneering force in the mining sector, poised to shape the future of clean energy. (8)
FOREMOST LITHIUM (NASDAQ: FMST) POSITIONED FOR SIGNIFICANT GROWTH AS ANALYST’S TARGET SUGGESTS 250% UPSIDE POTENTIAL FROM 52-WEEK LOW (2)(3)
Image Source (13)
Embracing the electric vehicle (EV) revolution, Foremost Lithium Resource & Technology (Nasdaq: FMST) stands poised for growth amidst a structural supply-demand imbalance in lithium, particularly for EV batteries.
Legislative incentives aimed at fostering North American-sourced lithium further bolster the company’s prospects, exemplified by the $7,500 tax credit for EV purchases, contingent on the origin of battery components, with plans to extend to critical minerals by 2025. (2)
At the forefront of its operations is Foremost Lithium Resource & Technology (Nasdaq: FMST)’s flagship Zoro Project, which boasts 25 confirmed spodumene-bearing pegmatite dykes.
The company’s upcoming 10,000m diamond drill campaign, commenced in February 2024, underscores its dedication to expanding its resource base and exploring new growth avenues. (18)
Beyond the Zoro Project, Foremost Lithium Resource & Technology (Nasdaq: FMST)’s expansive portfolio includes promising lithium properties in Manitoba and Quebec, alongside the Winston Gold & Silver Project in New Mexico.
An uplisting to NASDAQ under ticker symbol FMST augurs well for the company, opening new doors for expansion and investor engagement while enhancing visibility and liquidity. (2)
Supported by promising metallurgical studies indicating the potential for near battery-grade lithium concentrate, Foremost Lithium Resource & Technology (Nasdaq: FMST)’s Direct Shipping Ore (DSO) plan offers a viable strategy for monetizing ore and unlocking significant value from its assets.
Recent developments, including winter drill programs and securing financing commitments, underscore the company’s proactive approach to project advancement, further strengthened by its third installment of a $300,000 grant totaling $900,000 from the Manitoba Mineral Development Fund.(2)
With Zacks Small-Cap Research analyst Steven Ralston, CFA, setting a target of $6.20 for the company, Foremost Lithium Resource & Technology (Nasdaq: FMST) has garnered significant attention in the market.
This target suggests over 250% potential upside from the company’s 52-week low of $1.77, set on 10/25/2023, and over 113%potential upside from its recent opening of $2.90 on Monday, 2/12/2024. (2)(3)
However, the analyst target is just one piece of the puzzle.
When you consider the remarkably small float of Foremost Lithium Resource & Technology (Nasdaq: FMST), excitement is hard to contain. With less than 4.5M shares available in its float as of 2/12/2024, the potential for significant price movements becomes even more enticing. (6)
Low float stocks refer to the securities that remain after a company’s stock has been issued to its controlling investors — meaning there are relatively few shares for the public to buy. (7)
Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions. (7)
Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. (7)
That limited supply can cause dramatic price swings if demand changes quickly. (7)
Because low-float stocks have fewer shares available, market participants may have difficulty finding shares available. (7)
Foremost Lithium Resource & Technology (Nasdaq: FMST) has less than 4.5M shares available in its float (as of 2/12/2024) according to Finviz.com. (7) A low-float stock can make significant moves due to volatility from so few shares being available (7), so this could be one interesting situation to watch closely.
Foremost Lithium Resource & Technology (Nasdaq: FMST) is also considered a nano-cap. In general, nano-cap companies have market capitalizations of less than $50 million. (9)
Because nano-cap stocks are significantly smaller than mid cap or large cap companies, they have a higher potential to change valuation quickly. (10)
As of 2/12/2024, Foremost Lithium Resource & Technology (Nasdaq: FMST) has a market cap of less than $14M (approx.)according to FinViz.com. (6)
Overall, Foremost Lithium Resource & Technology (Nasdaq: FMST) has several positive catalysts, such as a $6.20 analyst target, its potential for growth and low public float, making it an attractive option for those looking to take advantage of swings with significant potential.
As the world transitions towards clean energy solutions, Foremost Lithium is well-positioned to emerge as a key player in the global lithium market, delivering long-term value while contributing to a sustainable future.
Foremost Lithium Resource & Technology (Nasdaq: FMST): Strategic Advancements Fueling The Clean Energy Future (8)
Foremost Lithium Resource & Technology (Nasdaq: FMST) is making waves in the North American hard-rock lithium exploration sector, strategically positioning itself to play a significant role in the clean energy economy. Headquartered in Vancouver, British Columbia, the company is focused on extracting lithium oxide, a crucial component in lithium-based batteries powering the electric vehicle (EV) revolution and the broader transition towards decarbonization. (8)
The company operates several strategically located properties, notably in Snow Lake, Manitoba, and Quebec, covering over 55,1180 acres. This extensive landholding places Foremost Lithium at the forefront of supplying North America’s burgeoning lithium demand, which is vital for the rapidly expanding EV and battery storage markets. (8)
Foremost Lithium Resource & Technology (Nasdaq: FMST) has embarked on a groundbreaking endeavor with the initiation of drilling operations at its Zoro Lithium Property nestled in the Snow Lake region of Manitoba.
Securing a multi-year work permit from the Manitoba Government’s Mining Permit Office until April 26th, 2026, marks a significant milestone for the company. This permit not only streamlines administrative processes but also lays the groundwork for extensive and sustained exploration efforts on the property.
Backed by a $300,000 grant from The Manitoba Mineral Development Fund, Foremost Lithium Resource & Technology (Nasdaq: FMST) is poised to make substantial strides in its exploration endeavors. This financial boost underscores the company’s commitment to advancing its projects and harnessing the full potential of the region’s lithium resources.
Jason Barnard, President and CEO of Foremost Lithium Resource & Technology (Nasdaq: FMST), expressed optimism about the venture, highlighting Dyke 1 as a key target for resource expansion. With the luxury of time afforded by the multi-year permit, the company aims to capitalize on the vast potential for resource augmentation and tonnage buildup.
Drilling operations kicked off at Dyke 8 in early February, building upon previous successes at the site. Encouraging lithium assay results from earlier drill intersections validate the promising nature of the project. With high-grade lithium discovered in spodumene-bearing pegmatite, the company is primed to uncover new intersections that could drive significant value for industry stakeholders.
The expansive nature of Dyke 8, spanning 120 meters in length and exhibiting widths of 5-15 meters, presents an enticing prospect for further exploration. With the dyke remaining open in all directions, Foremost Lithium Resource & Technology (Nasdaq: FMST) is eager to unlock its full potential through additional drill testing.
Image Source (18)
Beyond Dyke 8, Foremost Lithium plans to explore Dyke 3 and other spodumene-bearing dykes for resource expansion and development. These efforts align with the company’s strategic vision of enhancing its resource base and solidifying its position in the burgeoning lithium market.
At the heart of Foremost Lithium Resource & Technology (Nasdaq: FMST)’s endeavors lies Dyke 1, boasting an inferred resource of over a million tons of high-grade lithium-bearing spodumene pegmatite. With mineralization extending along a significant strike length and remaining open in all directions, Dyke 1 promises to be a cornerstone of the company’s future resource development initiatives.
The drilling campaign is bolstered by a dedicated team and robust logistical support. Rodren Drilling Ltd. provides the drill rig and crew, while Gogal Air Services offers air support and core storage facilities. Moss Line Cutting Ltd. handles drill pad preparation, ensuring seamless operations on the ground.
Image Source (18)
Technical expertise is provided by Dahrouge Geological Consulting, further enhancing the efficiency and effectiveness of the drilling program.
Although initially slated to commence after the Jean Lake property drilling program, Foremost Lithium opted to prioritize the Zoro Property’s Dyke 1, reflecting the company’s strategic focus on maximizing its most promising assets.
As Foremost Lithium embarks on this transformative journey, the commencement of drilling operations at the Zoro Lithium Property marks a pivotal moment in the company’s quest to unlock the full potential of Manitoba’s lithium riches.
With a robust strategy in place and a commitment to excellence, Foremost Lithium Resource & Technology (Nasdaq: FMST) is poised to make substantial strides in the lithium industry.
Emerging Trends In Lithium And Gold Markets
The global shift toward renewable energy is facing a critical supply challenge, necessitating significant investment in the battery supply chain.
According to industry analysis, approximately $514B of investment by 2030 is required to meet expected demand, highlighting the importance of companies like Foremost Lithium.
Image Source (16)
Simultaneously, the gold market is experiencing a significant upswing, with declining interest rates and geopolitical risks expected to push prices to new highs in 2024.
These developments underscore the growing demand for mineral exploration and the growth potential of key players like Foremost Lithium.
Pioneering The Future Of Clean Energy
Image Source (17)
Foremost Lithium Resource & Technology (Nasdaq: FMST)’s recent achievements, coupled with the growing demand for lithium and gold, highlight the company’s potential as a formidable player in North America’s mining sector.
With initiatives like the multi-year work permit, MMDF grant, and extensive drilling programs, Foremost Lithium is poised to become a premier supplier of lithium feedstock, crucial for the EV and battery storage markets and the broader shift towards sustainable energy solutions.
Considering the potential upside of over 250% from its 52-week low (2) and a global lithium-ion battery market forecasted to surge over 295% by 2032,(4) it’s evident why Foremost Lithium Resource & Technology (Nasdaq: FMST) demands immediate attention.
Positioned strategically in the electrification revolution, Foremost Lithium Resource & Technology (Nasdaq: FMST) focuses on extracting lithium oxide, essential for EV batteries, and boasts an expansive portfolio across North America. (8)
Furthermore, with an ultra-low float and significant growth catalysts, (6)(7) Foremost Lithium Resource & Technology (Nasdaq: FMST) is primed to capitalize on the clean energy future, making it a compelling prospect for industry stakeholders seeking exposure to the burgeoning lithium market.
JASON BARNARDCEO And President, And Non-Independent Executive Board MemberJason BarnardMr. Barnard has over 31 years of capital markets experience. Since 2004, he has been self-employed as a private investor where he has been directly involved in raising over $500 million dollars for mining and exploration companies with a focused expertise on Canadian base metal companies.
Mr. Barnard started his career with McDermid St. Laurence Securities in 1991 as a stockbroker with primary focus in mining, and mining exploration companies. Mr. Barnard then worked at Canaccord Genuity from 1997 until 2004. Mr. Barnard holds a Bachelor of Arts degree with a major in Economics from Carlton University and has obtained The Canadian Securities Course license in 1990. He first started working with and financing Foremost Lithium, previously known as Far Resources, with founder, and President Keith Anderson in 2016 and is the Company’s largest shareholder.
BAL BHULLAR, CPA,CGA,CRMChief Financial Officer & Corporate SecretaryBal BhullarBal Bhullar Ms. Bhullar has more than 25 years’ experience in senior financial positions, risk management experience as an executive and/or board director, in both public and private companies. She is a Chartered Professional Accountant, Certified General Accountant, and holds a CRM designation from Simon Fraser University and a diploma in Financial Management from British Columbia Institute of Technology. Ms. Bhullar brings strong banking relationships and is experienced with increasing market capitalization, raising capital, corporate governance, ESG, diversity, financial & strategic planning, initial public offerings, reverse takeovers, operational & risk management, and regulatory compliance reporting. Ms. Bhullar is accomplished in all facets of business, and accounting has a diversified background including working in the technology, automotive, resource, energy, transport, blockchain, e-commerce, and manufacturing industries.
Most recently, Ms. Bhullar served as CFO and executive board member at ElectraMeccanica (Nasdaq: SOLO), where she was responsible for managing the financial initiatives essential to the company’s growth. Her involvement at ElectraMeccanica was instrumental through its evolution in scaling an EV manufacturer from its early stages through its through its NASDAQ listing.CHRISTINA BARNARDChief Operating OfficerChristina BarnardChristina Barnard has been part of the organization since August 2020. She brings over 20 years’ experience in business management, media and marketing where she spent over ten years working for a well-known national public company, as senior marketing and media advisor.She has worked with a number of public companies, including roles in corporate communications and strategist. Christina has helped facilitate a number of different organization’s objectives, via careful evaluation and strategic planning, assessing structure and procedures, and being able to administer their core values in a clear demonstrable way both internally and in in the general public.
MARK FEDIKOW PH.D. P.GEO. CPGGeoscientific AdvisorMark FedikowDr. Fedikow has over 40 years of experience as an exploration geochemist and a mineral deposits geologist working in both private and public sectors. He is a Fellow at the Association of Applied Geochemists, where he’s previously worked as a councilor. Dr. Fedikow has also served on numerous industry-related committees. He also pioneered the application of regional multimedia geochemical and mineralogical surveys in support of base and precious metal and diamond exploration in Manitoba.
During his 45-year career he has worked for a variety of junior and major mining exploration and mining companies and for the Manitoba Geological Survey as Chief Geologist of the Mineral Deposits Section. In 2001 he received the Provincial Geologists gold medal, a Canadian national award for excellence in the geosciences.In 2002 Mark left the Manitoba Geological Survey to start his own company (Mount Morgan Resources Ltd.) providing consulting services to the metal and hydrocarbon exploration industry. He is currently registered as P.Eng. and P.Geo. with Engineers Geoscientists Manitoba (“EGM”), P.Geo. with the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists (NAPEG) and as a Certified Professional Geologist (C.P.G.) with the American Institute of Professional Geologists (“A.I.P.G.”), Westminster, Colorado, U.S.A.
JODY DAHROUGE, B.SC., SP.C., – P. GEOL.Geological AdvisorJody DahrougeMr. Dahrouge has been the President of Dahrouge Geological Consulting Ltd., a North American mineral exploration, consulting, and project management group, since 1988. He is a professional geologist with over 30 years’ experience and holds Bachelor of Science degrees in geology and computing science, both from the University of Alberta.
Mr. Dahrouge has been involved in all aspects of mineral exploration and development for a wide variety of commodities worldwide. Dahrouge Geological Consulting Ltd. has been instrumental in a multitude of grassroots discoveries across a wide variety of commodities and currently has boots on the ground on multiple Canadian and American projects.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF ELEVEN THOUSAND USD BY TD MEDIA LLC FOR A ONE DAY FMST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
TOON REPORTED REVENUE OF $10.1 MILLION AND $35.3 MILLION, FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023
KARTOON CHANNEL! ANTICIPATES FIRST EVER BREAK-EVEN EBITDA IN FOURTH QUARTER OF 2023, A FIRST SINCE ITS LAUNCH
NEW CFO BRIAN PARISI BRINGS STRONG TRACK RECORD FROM THE NFL AND LIVE NATION, FOCUSED ON VALUE CREATION, AS WELL AS GROWING REVENUES AND DRIVING SUSTAINABLE EARNINGS
THE CHANNEL’S VIEWER RANKINGS CONTINUE TO OUTPERFORM ALL OF ITS MAJOR COMPETITORS IN THE APPLE APP STORE, WITH 4.9 OUT OF 5 STARS, BESTING DISNEY+, NETFLIX KIDS AND YOUTUBE
We have another profile on deck for Monday’s session.
We wanted to get this one out today before the start of the game. (We are riding with the 49ers -2)
This one has several catalysts that you should research heading into Monday.
This one generated over $62M in revenues in 2022 and released some impressive numbers thus far for 2023.
Pull up TOON immediately.
ANALYST COVERAGE:
Dawn James analyst James McIlree’s bullish $10 target for Kartoon Studios Inc. (NYSE: TOON) suggests an astonishing 941% upside potential from the company’s 52-week low and over 706% in potential upside from its recent $1.24 opening on 2/8/2024 according to Barchart.com. (1)(3)
EXPLOSIVE GROWTH POTENTIAL:
On the brink of a content revolution in 2024, Kartoon Studios Inc. (NYSE: TOON) is poised to flood the market with a diverse array of captivating storytelling and vibrant animation. With a strategic focus on revenue enhancement and operational optimization, the company is primed to unlock unprecedented growth opportunities. (2)
BREAKTHROUGH STREAMING SUCCESS:
Kartoon Channel!, the company’s streaming network, achieved a groundbreaking milestone in 2023 by reaching breakeven just three years after its launch. (2)
DIVERSE PORTFOLIO OF INTELLECTUAL PROPERTIES
Boasting an impressive lineup, Kartoon Studios Inc. (NYSE: TOON) has original IPs, ranging from legendary Stan Lee Universe creations to adventurous narratives like Blue Origin Space Rangers and the quirky Chikn’ Nuggit. With collaborations with industry titans like Netflix, Disney Channel, and Frederator Networks, Kartoon Studios offers market observers exposure to a diverse array of storytelling treasures poised for global distribution. (2)
VISIONARY LEADERSHIP
With Gregg Goldin at the helm of content expansion as Senior Vice President of Development & Production, Kartoon Studios Inc. (NYSE: TOON) is poised to enter a new era of creative dynamism. Goldin’s unparalleled expertise and visionary leadership, honed through decades of experience at DreamWorks Animation, Cartoon Network, and MTV, position him as a driving force behind Kartoon Studios’ content renaissance. His track record of nurturing successful franchises and forging strategic partnerships underscores the company’s potential for delivering blockbuster results. (2)
_________________________
In the ever-evolving landscape of children’s entertainment, Kartoon Studios Inc. (NYSE: TOON) emerges as a shining beacon of creativity and innovation. With a diverse portfolio of animated properties and a strategic focus on global distribution, Kartoon Studios is poised to captivate audiences worldwide while delivering substantial research opportunities to market observers.
Analyst James McIlree, CFA of Dawson James Securities, recently set a $10 target on Kartoon Studios, suggesting an impressive 969% upside potential from the company’s 52-week low of $.9346, set on 10/31/2024, according to Barchart.com. (1)(3)
Additionally, with its recent opening on 2/8/2024 at $1.24, the $10 target implies a remarkable 706% potential upside. This optimistic projection underscores the company’s transformative journey and its promising outlook for future growth and profitability. (1)(3)
EXPANDING HORIZONS WITH SHAQ’S GARAGE (1)
One of Kartoon Studios’ standout offerings is “Shaq’s Garage,” an animated series starring none other than basketball legend Shaquille O’Neal. (1)
Launched in June on Pluto TV, “Shaq’s Garage” exceeded expectations, driving significant audience engagement and surpassing viewership numbers of all other Kartoon Channel titles combined. (1)
The availability of “Shaq’s Garage” across all Kartoon Channel platforms further solidifies its status as a cornerstone of the company’s content lineup, poised to drive higher revenue in the second half of the year. (1)
STRATEGIC ACQUISITIONS AND INVESTMENTS (1)
Kartoon Studios has undergone a remarkable transformation over the past 12 months, positioning itself as a global developer, producer, and distributor of animated children’s content.
Key acquisitions, including WOW Unlimited and Ameba TV, along with an investment in Your Family Entertainment AG (YFE), have significantly enhanced the company’s content creation capabilities and global distribution reach. (1)
With access to independently created content from WOW’s YouTube multi-channel network and YFE’s extensive distribution network spanning Europe, Asia, Latin America, Africa, and Australia, Kartoon Studios is well-positioned to reach audiences across the globe. (1)
FINANCIAL STRENGTH AND STRATEGIC INITIATIVES (1)
Kartoon Studios Inc. (NYSE: TOON) reported revenue of $10.1 million and $35.3 million, for the three and nine months ended September 30, 2023. As of September 30, 2023, Kartoon Studios had current assets of $61.4 million, working capital of $11.8 million, and total stockholders’ equity of $74 million. (8)
VALUATION AND GROWTH POTENTIAL (1)
McIlree’s $10 price target for Kartoon Studios is based on a comparable group of entertainment companies trading at 3x to 5x sales. Utilizing a conservative 4.5x sales multiple and a Q4 2024 run rate revenue estimate of $72 Mln, the target price reflects the company’s immense potential and compelling valuation. (1)
A GLOBAL FORCE IN CHILDREN’S ENTERTAINMENT
Kartoon Studios Inc. (NYSE: TOON) stands out as a unique and dynamic player in the entertainment industry, with a global distribution reach and a rich portfolio of beloved animated properties. (1)
With Shaq’s Garage leading the charge and a robust pipeline of content on the horizon, Kartoon Studios is poised to redefine the future of children’s entertainment for years to come. (1)
GLOBAL ANIMATION MARKET PREDICTED TO SKYROCKET TO $779B(4)
Chart Source (4)
The global animation market is on a trajectory of unprecedented growth, with estimates projecting it to surpass a staggering $779B by the year 2032. (4)
A recent research report delving into the realm of the “Kids Animation Show and Drama Market” offers a glimpse into this booming industry, providing insightful perspectives and future market projections. (5)
Surprisingly, within a mere four years, the global market for Kids Animation Show and Drama is expected to skyrocket to $8.3B by 2028, underscoring the rapid pace of expansion within this sector. (5)
DRIVING FORCES BEHIND MARKET EXPANSION
A pivotal driver propelling the growth of the animation industry is the relentless surge in technological advancements within the realms of communication and technology. (4)
The emergence of revolutionary technologies such as virtual reality (VR) and artificial intelligence (AI) is poised to unlock new avenues of opportunity for market players worldwide. (4)
Extended Reality (XR) technologies, including VR and AI, are witnessing remarkable advancements, revolutionizing the creative landscape of the animation industry. (4)
The transformative potential of AI is set to redefine industrial growth, offering a myriad of opportunities for key players operating within the market. (4)
Additionally, the rising adoption of visual effects technology in movies further augments the growth trajectory of the industry, promising substantial expansion though 2032.(4)
STRATEGIC PARTNERSHIPS: CATALYSTS FOR MARKET GROWTH (4)
A notable trend observed within the global market is the proliferation of strategic partnerships among major industry players.
This collaborative approach is anticipated to persist and serve as a significant catalyst for market expansion in the foreseeable future, fostering innovation and driving growth across the sector. (4)
Amidst the backdrop of this dynamic market landscape, Kartoon Studios Inc. (NYSE: TOON) emerges as one company to keep a close eye on. (6)
Kartoon Studios Inc. (NYSE: TOON), a leading global media company, specializes in developing, producing, marketing, and licensing branded animated properties and consumer products for media and retail distribution. (6)
A DIVERSE PORTFOLIO OF FAMILY-FRIENDLY CONTENT
Kartoon Studios Inc. (NYSE: TOON) boasts an impressive IP portfolio, featuring a plethora of family-friendly content that resonates with audiences worldwide. (6)
Chart Source (12)
From the iconic Stan Lee brand and “Stan Lee’s Superhero Kindergarten” starring Arnold Schwarzenegger to the eagerly anticipated “Shaq’s Garage” featuring basketball legend Shaquille O’Neal, Kartoon Studios offers a rich tapestry of animated entertainment.
Notable productions include “Rainbow Rangers” on Kartoon Channel and Netflix, as well as “Llama Llama” starring Jennifer Garner, also on Netflix. (6)
STRATEGIC ACQUISITIONS AND GLOBAL DISTRIBUTION REACH
In a strategic move to bolster its market presence, Kartoon Studios Inc. (NYSE: TOON) entered into an agreement to acquire Canada’s WOW! Unlimited Media, adding over 2,000 channels under the Channel Frederator Network to its repertoire. (6)
Image Source (13)
Additionally, the company made a strategic investment in Germany’s Your Family Entertainment AG, further expanding its reach in Europe. (6)
Kartoon Studios’ Toon Media Networks, comprising Kartoon Channel!, Frederator Network, and Ameba, constitutes a globally distributed entertainment platform with extensive penetration in the U.S. television market and a burgeoning international presence across 60 territories worldwide. (6)
Under Kartoon Studios’ umbrella, Frederator Network reigns as the largest global animation network on YouTube, boasting over 2,000 exclusive creators and influencers.
With billions of views garnered every month, Frederator Network serves as a testament to Kartoon Studios’ commitment to fostering creativity and nurturing talent in the animation community.
Image Source (15)
KARTOON STUDIOS INC. (NYSE: TOON) SETS SAILS FOR A BANNER YEAR WITH A CONTENT TSUNAMI IN 2024 (2)
Image Source (14)
Kartoon Studios Inc. (NYSE: TOON) is poised to unleash a wave of content in 2024, signaling an ambitious leap forward in its mission to captivate audiences with imaginative storytelling and vibrant animation.
With a strategic focus on boosting revenue and optimizing operations, the company is charting a course towards sustained profitability, buoyed by the resounding success of its streaming network, Kartoon Channel! (2)
Chief Financial Officer, Brian Parisi, underscores the pivotal role of revenue-driving initiatives and operational efficiency in steering Kartoon Studios towards profitability. (2)
The company’s streaming service, Kartoon Channel!, achieved a breakthrough in 2023 by reaching breakeven, a remarkable feat within just three years of its launch. (2)
As Kartoon Channel! continues its ascent, dominating user rankings in the Apple app store among children’s content platforms, the stage is set for further financial milestones in 2024, aligning the company’s trajectory with industry giants like Netflix. (2)
Image Source (2)
At the helm of Kartoon Studios Inc. (NYSE: TOON)’s content expansion is Gregg Goldin, a luminary in animation and content development. (2)
Goldin’s illustrious career boasts stints at DreamWorks Animation, Cartoon Network, and MTV, where he played instrumental roles in shepherding iconic franchises and groundbreaking series to fruition. (2)
His appointment as Senior Vice President of Development & Production heralds a new era of creative dynamism for Kartoon Studios, infused with his wealth of experience and visionary leadership.(2)
Goldin’s arrival coincides with an exciting lineup of projects poised to captivate audiences worldwide. (2)
From original IPs sourced from the legendary Stan Lee Universe to adventurous narratives like Blue Origin Space Rangers and the quirky Chikn’ Nuggit, Kartoon Studios is primed to unleash a diverse array of storytelling treasures. (2)
Collaborations with industry titans such as Netflix, Disney Channel, and Frederator Networks underscore the company’s commitment to delivering premium content across multiple platforms.
Image Source (10)
Andy Heyward, Chairman & CEO of Kartoon Studios, expresses his enthusiasm for the forthcoming wave of creative endeavors, highlighting Goldin’s invaluable contributions in fortifying the company’s content arsenal. (2)
With Goldin spearheading development and production efforts, Kartoon Studios aims to cultivate a rich tapestry of intellectual properties poised for global distribution, mirroring Goldin’s previous successes in shepherding blockbuster franchises to fruition.(2)
Goldin’s track record of nurturing successful series and movies at DreamWorks Animation and Cartoon Network positions him as a pivotal architect in Kartoon Studios’ content renaissance. His adeptness in fostering partnerships and driving innovation underscores his instrumental role in propelling Kartoon Studios towards unprecedented heights of creative excellence and commercial success.(2)
Image Source (11)
In the rapidly evolving landscape of children’s entertainment, Kartoon Studios Inc. (NYSE: TOON) stands out as a beacon of creativity and innovation. With an expanding portfolio of original IPs, strategic partnerships, and a growing streaming platform, the company is poised to captivate audiences of all ages, reaffirming its position as a global leader in positive entertainment for children.
As Kartoon Studios Inc. (NYSE: TOON) embarks on its journey into 2024 and beyond, the stage is set for a symphony of storytelling brilliance, orchestrated by the industry’s finest talents and fueled by an unwavering commitment to delight, inspire, and entertain audiences around the world.
Emmy Award-winning Andy Heyward has made more episodes of kid’s television than any other producer. After graduating from UCLA with a Bachelor of Arts degree in Philosophy in 1975, he joined Hanna-Barbera as a writer and story editor. During his five years with Hanna-Barbera, he was involved in the development and writing of numerous series including Scooby Doo, Flintstones, Jetsons, Smurfs, Yogi Bear and Scooby’s All Star Laff-A-Lympics. In 1980 he moved to France where he joined DIC Audiovisual, a production company specializing in children’s animated programming. In 1982, he co-created Inspector Gadget and during the following years he has produced over 5,000 episodes of award-winning children’s programs, most of which shows and brands are household names, including Inspector Gadget, The RealGhostbusters, Alvin and the Chipmunks, G.I. Joe, Hello Kitty, Sonic the Hedgehog, Super Mario Bros, Sabrina the Teenage Witch, Strawberry Shortcake, Care Bears, Captain Planet, Teddy Ruxpin, Sailor Moon, Madeline, Where on Earth is Carmen Sandiego, Liberty’s Kids, and dozens more. In 1994, he convened the National PTA, National Education Association, UCLA and producers from throughout the industry to draft the first voluntary set of program guidelines for children’s television. In 1996, he hosted the first meeting between then FCC Chairman Reed Hundt and children’s television producers.
Today under Kartoon Studios, Heyward produces and licenses brands ranging from Stan Lee Universe, to Baby Genius, to Warren Buffett’s Secret Millionaires Club, to Thomas Edison’s Secret Lab, to SpacePop for the global market. He has also been the largest producer of FCC mandated educational informational programming for children, and has produced hundreds of PSAs promoting child safety, health, exercise, and nutrition. In collaboration with Warren Buffett, he produces the short film which opens the annual Berkshire Hathaway Shareholders meeting, and he co-authored a book with Warren Buffett promoting financial literacy for kids. Heyward is also the author of Go Go Gadget – The Creation of Inspector Gadget.
Andy’s notable work in children’s programming has earned him multiple industry awards, and his charitable efforts off-screen have resulted in numerous recognitions. Some of his awards include two Emmys, nine Emmy nominations, two Humanitas Awards, two Cable Ace Awards, five Golden Reel Awards, three Environmental Media Awards, a New York Television Festival Award and a National Education Association Award, among others. He was inducted into the KidScreen Hall of Fame, and won the Studio of the Year at Italy’s Cartoons on the Bay International Festival of Television Animation in 2006 (co-awarded to Roy Disney).
Heyward is a member of the Producers Guild of America, the National Academy of Television Arts and Sciences, the International Academy of Television Arts and Sciences, and the British Academy of Film and Television Arts (BAFTA). He was the 2010 UCLA College of Humanities Commencement speaker and is currently a Mentor in the UCLA mentoring program. He is active in many community activities, including serving on the Board of Directors of Cedars-Sinai Medical Center.
MARGARET LOESCH
Executive Chairman Kartoon Channel!
Throughout her formidable career, Margaret Loesch has held senior roles with numerous leading companies as both a creative and business executive. In 1990, she became the founding President and CEO of Fox Kids Networks Worldwide, growing the channels across all metrics, where it was eventually sold to the Walt Disney Company for $5.5 billion. During this time, she launched a multitude of hit series, including the billion-dollar brand Power Rangers, growing Fox Kids into the top children’s program service on television.
Prior to Fox Kids, Loesch served as President & CEO of Marvel Productions. Previously, she was President of The Jim Henson Company, and the Founding President & CEO of the U.S. Hallmark Channel and Crown Media U.S. Most recently, Loesch served as President of the HUB, which was a joint venture between Hasbro Toys and Discovery Communications, where she had oversight of all business and creative areas of the network. In addition to Power Rangers, her resume includes launching some of the most successful animated children’s properties in the world, such as Batman, Spider-Man, Steven Spielberg’s Animaniacs, Transformers, My Little Pony, X-Men, Muppet Babies, and Fraggle Rock.
MICHAEL JAFFA
Chief Operating Officer
Michael Jaffa served as Head of Business Affairs at DreamWorks Animation Television and was responsible for all studio business and legal affairs matters, including the negotiation and drafting of hundreds of development, production, acquisition, talent, digital and music agreements. Previously, he was the Vice President of Legal & Business Affairs for Hasbro Studios, working directly with Hasbro Studios’ President, CFO, and General Manager to help create programs and launch strategy for a new studio and related network. Michael has also represented various clients, including Sony Pictures Animation and MGM Studios. Michael received a J.D. from New York University School of Law.
BRIAN PARISI
Chief Financial Officer
Mr. Parisi brings 30 years of experience across the entertainment, media, and high-tech industries, specializing in finance, accounting, M&A, corporate strategy, and business development. Before joining Kartoon Studios, he was the Chief Financial Officer at Break the Floor Productions in Hollywood, California, an entertainment production company. In this role, he notably prepared the company for sale, successfully completing two separate transactions with PE firms. He managed all finance and accounting functions and effectively reduced the company’s overall risk exposure. Previously, Mr. Parisi served as the Chief Financial Officer at the NFL Hall of Fame Village (HOFV), where he oversaw a wide range of financial activities including managing construction budgets, assist the company with its IPO, financial reporting, and cash management for the nearly $1 billion investment in a newly designed entertainment complex in Canton, Ohio. In addition, he served as the Head of Finance for the Festivals Division at Live Nation Entertainment (LYV) where he was responsible for developing strategic plans for Electronic Dance Music festivals in multiple countries with more than 1.3 million fans annually. Mr. Parisi has also held leadership positions at Warner Bros. Entertainment (WBD) and NBC Universal (CMCSA).
Mr. Parisi is a CPA and holds a B.S. in Accounting from Purdue University, Daniel School of Business, and an M.B.A in Strategic Management from the University of Southern California, Marshall School of Business.
JON OLLWERTHER
Executive Vice President
Ollwerther joins Kartoon Studios from Measure, the nation’s leading Drone as a Service® company. As Vice President of Media, Ollwerther grew the Arts & Entertainment division from its inception and worked with leading media companies and advertisers like ABC, CBS, ESPN, Red Bull Media House, Coach, Prada, Maker’s Mark, and Nissan.
As a trailblazer in an emerging industry, Ollwerther focused on leveraging drones as a tool for artistic expression and informational use, including major franchise films to live concerts and events. Among other accomplishments, he pioneered live broadcasting via drone for news and sports and spearheaded the first live drone network broadcasts in America, and helped bring drone light shows to life. Working with clients across the country and around the world, Ollwerther has an extensive credit list of collaborations with brands and advertising agencies to create unforgettable experiences. Prior to joining Measure, Ollwerther was the COO of an aerial robotics company based in NYC.
LLOYD MINTZ
Senior Vice President, Head of Worldwide Consumer Products
Lloyd Mintz is a seasoned industry executive with more than 20 years of experience in licensing, merchandising and new business development and is widely respected for his expertise in leveraging brand equity through licensing. He works with retailers and licensees to build comprehensive global consumer products’ programs for each of the company’s brands. Prior to Kartoon Studios, Lloyd managed his own consultancy during which time he negotiated more than 150 licensing agreements and generated over $700MM in cumulative retail sales on behalf of clients across a range of brand owners and manufacturers. Most recently, he worked as Executive Vice President of Licensing for NYC-based Galaxy Brands that owned the AND1 and AVIA athletic brands. Previously, Lloyd worked at Hasbro, Inc. as the Vice President of Domestic Corporate Licensing where he pioneered the effort to license Hasbro’s classic game brands, such as Monopoly, to slot machine manufacturers. He began his licensing industry career at Disney Consumer Products where he oversaw Disney’s largest licensee, Mattel, Inc., and their development of toy programs for classic properties such as Lion King, Winnie the Pooh, and Aladdin. Lloyd graduated from Wesleyan University and earned his M.B.A. from UCLA’s Anderson School of Management.
GREGG GOLDIN
Senior Vice President, Development & Production
Goldin joins Kartoon Studios with over twenty years of experience in animation and live-action content development and production, overseeing highly successful movies and series across multiple genres, including DreamWorks Animation’s blockbuster franchises How to Train Your Dragon, Kung Fu Panda, and Fast & Furious. In this new role, Goldin will be responsible for heading up development and production for both new and original IP to deliver to the marketplace.
CINDY KELLY
President of Beacon Media Group
Kelly joins Kartoon Studios with over 25 years of experience in executive sales and sponsorship roles at leading media companies, including extensive children’s media sales at Cartoon Network. She also served as Broadcast Account Supervisor at Ogilvy & Mather Advertising in NYC, overseeing media strategy for blue chip accounts, including, Mattel Toys, Campbell’s Soup and Paramount Pictures.
TODD STEINMAN
President of Toon Media Networks
Todd Steinman is an accomplished growth marketing executive who with extensive B2B and B2C experience. Prior to joining Kartoon Studios, Steinman most recently served as Vice President in the Direct to Consumer and International division at The Walt Disney Company, which included Disney+ during its launch. He helped create solutions to leverage the Walt Disney Company’s portfolio of linear and digital brands, including DISNEY, HULU, ESPN, ABC, FREEFORM, FX, and Nat Geo, while setting strategy for ad sales and revenue teams. Prior to his role at The Walt Disney Company, Steinman co-founded the digital media agency, M80, and then led the NBC Universal media team for WPP after they acquired M80. He negotiated multi-million-dollar annual media deals with Google/YouTube, Amazon, Hulu, Disney, Twitter, Snapchat, Spotify, and others, while managing an annual budget north of $1 billion.
PAUL ROBINSON
President of Kartoon Channel! Worldwide
Paul Robinson is an accomplished and seasoned media executive with significant experience developing media brands around the globe. Robinson previously served as Managing Director of Disney Channel Worldwide, where he was responsible for global programming and production strategy. He also founded the Toon Disney and Playhouse Disney television channels internationally. Before his tenure at The Walt Disney Company, Robinson was Head of Strategy for the BBC Newtork Radio, overseeing the strategy development for BBC Radios 1, 2, 3, 4, and 5 Live. Additionally, he has served as Managing Director of talkSPORT; Co-Founder and CEO of KidsCO, NBCUniversal’s international children’s channel; and Executive Vice President of Your Family Entertainment AG, in which Kartoon Studios recently acquired a controlling stake.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF ELEVEN THOUSAND USD BY TD MEDIA LLC FOR A ONE DAY TOON AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We have a new Nasdaq profile for tomorrow’s session that is hovering around .10 with planned merger upcoming.
Pull up BRSH immediately
BRSH has developed its sonic-powered Bruush electric toothbrush to make upgrading to an electric brush appealing.
Did you know that when you brush manually, you average only 200 brush strokes a minute while our Brüush provides up to 42,000 sonic vibrations per minute? That’s over 200x more than your manual!
This is a game-changing electric toothbrush that is attracting many subscribers already.
Through their website, consumers can purchase a Brüush starter kit, which includes: (i) the Brüush electric toothbrush; (ii) three brush heads; (iii) a magnetic charger; and (iv) a travel case. They developed the product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. Brüush is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.
There are now over 38,000 active subscriptions in its brush head refill program and the Company’s internal research demonstrated that over 85% of subscribers are interested in adding Consumables to their existing subscriptions.
Electric toothbrushes are superior to manual, but the majority of people have not switched
Studies have shown that electric toothbrushes are more effective than manual toothbrushes1
Despite clear oral care benefits, most people still use a traditional manual toothbrush2
The low adoption rate shows that consumers do not find the current electric toothbrush value proposition compelling
They have received over 3,000 organic reviews with a 90% 5-star rating
Their return rate is less than 1%, compared to a U.S. national average return rate of 21% for online purchases
Their annual churn rate on active subscriptions is only 12%, whereas Dollar Shave Club and Harry’s both have an annual churn rate of almost 70%
BRUUSH ORAL CARE INC. AND ARRIVE TECHNOLOGY INC. ANNOUNCE AGREEMENT AND PLAN OF MERGER
VANCOUVER, BC and INDIANAPOLIS, IN / ACCESSWIRE / December 15, 2023 / Bruush Oral Care Inc.(Nasdaq:BRSH) (“Brüush”) and Arrive Technology Inc. (“Arrive”), a technology company focused on facilitating the last inch of the last-mile for autonomous delivery, today announced they have entered into an agreement and plan of merger. The combined company (“Combined Company”) will focus on the advancement and implementation of Arrive’s smart Mailbox-as-a-Service (MaaS) platform that makes the exchange of goods between people, robots and drones frictionless through the use of artificial intelligence (“AI”). The Combined Company is expected to operate under the name Arrive Technology Inc. with its shares listed on the Nasdaq Capital Market under the ticker symbol ‘ARRV’.
“We are thrilled to announce this proposed merger with Arrive,” remarked Aneil Manhas, Chief Executive Officer of Brüush. “In a world hungry for a future of automated last-mile delivery, there is a critical need for a smart and secure exchange point, which Arrive is poised to redefine with its smart mailbox technology. Arrive’s strong management team, robust IP portfolio and unique Mailbox-as-a-Service platform that integrates artificial intelligence (AI) and machine-learning capabilities, positions the company well to sit at the center of the autonomous delivery network in the evolving landscape of automated exchanges. We reviewed and evaluated numerous strategic alternatives for creating stockholder value and believe this transaction with Arrive presented the most compelling option for our shareholders.”
Arrive’s Chief Executive Officer Dan O’Toole said: “We are excited about becoming Indiana’s 42nd publicly listed company and are confident our AI-powered MaaS platform will deliver excellent value to existing shareholders of both Arrive and Brüush, as well as new shareholders. This agreement and plan of merger will accelerate the development and deployment of our third-generation smart mailbox and continue to support the autonomous delivery revolution.”
About the Transaction, Management and Organization
Under the terms of the merger agreement, Brüush and Arrive will conduct a business combination in the form of a reverse triangular merger (“Merger”) via an all-stock transaction. Brüush (“PubCo”) through its wholly owned subsidiary (“Merger Sub”) will merge with and into Arrive (“Target Company“) with Target Company continuing under the name of Arrive Technology Inc. and as a wholly owned subsidiary of PubCo.
Upon completion of the Merger, the outstanding shares of Target Company’s common stock, will be exchanged for common shares of PubCo representing upon issuance, 94.5% of PubCo’s issued and outstanding common shares on a fully diluted basis. The legacy shareholders of PubCo will own shares of PubCo common shares representing 5.5% of PubCo’s issued and outstanding common shares on a fully diluted basis. The merger has been approved by the board of directors of both companies and is expected to close in the first quarter of 2024, subject to customary closing conditions.
Prior to closing, PubCo will, among other things, effect a reverse stock split with respect to PubCo’scommon shares at a ratio within the range of 6-for-1 to 200-for-1. Additionally, PubCo, will maintain a net cash minimum of US$10,000,000 consisting of cash and cash equivalents after full payment of current liabilities, including any financing and expenses in connection with the Merger. After the closing of the Merger, PubCo will sell, transfer and assign all existing legacy business, assets and liabilities of PubCo to a purchaser and pursuant to that certain separation and distribution agreement to be entered into by and between PubCo and such purchaser on terms and conditions to be mutually agreed by PubCo and such purchaser.
Additional information and details about the transaction will be provided in a Form 6-K which will be filed by Brüush with the Securities and Exchange Commission (“SEC”) and will be available at www.sec.gov.
The Combined Company will focus on advancing Arrive’s existing operations as a technology company with a focus on designing and implementing a Mailbox-as-a-Service platform that facilitates smart, secure and seamless exchange of packages between people, robots and drones. Arrive’s patented smart mailbox system leverages climate-assisted cargo space, smart alerts and advanced chain of custody controls to secure the last inch of the last-mile for all shippers, delivery services and autonomous delivery networks. Arrive’s solutions are critically and uniquely positioned in the supply chain to leverage its unique data assets for artificial intelligence to provide users with machine-learning based insights that can aid businesses and consumers to lower logistical costs and capture new growth opportunities, among other benefits.
Following the consummation of the Merger, the Combined Company will be headquartered in Indianapolis, Indiana and it is anticipated that the Combined Company will be led by current members of the Arrive management team, including:
●
Dan O’Toole, Chief Executive Officer
●
Todd Pepmeier, Chief Financial Officer
●
Mark Hamm, Chief Operations Officer
●
Torrey Bievenour, Chief Technology Officer
●
Neerav Shah, Chief Strategy Officer
●
Lora O’Toole, Vice President Business Development
●
John Ritchison, Corporate Counsel
The Board of Directors of the Combined Company is expected to consist of five members, one of which will be designated by Brüush and the remainder will be designated by Arrive.
ARRIVE ACQUIRES AIRBOX TECHNOLOGIES IN ADVANCE OF BRÜUSH MERGER
ACQUISITION BROADENS PATENT PORTFOLIO AND PROPELS ARRIVE’S SMART MAILBOX AS A SERVICE CAPABILITIES
VANCOUVER, BC and INDIANAPOLIS, IN / ACCESSWIRE / December 18, 2023 / Bruush Oral Care Inc. (Nasdaq:BRSH) (“Brüush”) announced today that its pending merger partner, Arrive Technology Inc. (“Arrive”), a technology company focused on facilitating the last inch of the last-mile for autonomous delivery, has acquired AirBox Technologies (“AirBox”). This acquisition includes AirBox’s patent portfolio, which Arrive believes will broaden the capabilities of its high-tech mailbox system designed for autonomous and conventional package delivery. In addition to acquiring the patent portfolio, AirBox’s CEO Brandon Pargoe has joined the Arrive team as Vice President of Product Operations.
Mr. Pargoe, who has a background as a medical grade manufacturer and telecom network engineer, founded AirBox in 2015 with the goal of delivering medications to remote locations. Based in Falls Church, Virginia, AirBox offers two smart solution products: Airbox Home and Airbox Deep. Both products offer an app-controlled, industrial grade, web-connected package delivery solution. Additionally, Airbox has secured patents pertaining to winch capabilities, a key component for autonomous delivery drones. Airbox was the first to fly drones beyond a visual line of sight with partners in Antigua, in collaboration with the government of Antigua, the United Nations Office for Project Services and ACT Antigua.
“We are excited to welcome AirBox and Brandon to our team. We believe his extensive background in technology, medical grade manufacturing and marketing will be accretive to our business,” stated Arrive CEO Dan O’Toole. “AirBox holds patents that extend beyond their smart mailbox, covering the entire drone delivery process. We regard this acquisition as a valuable addition to our patent portfolio, a pivotal asset for our organization.”
Mr. O’Toole added that just like Arrive, AirBox was meticulously developed from the ground up and its innovative intellectual property reinforces Arrive’s standing at the forefront of smart mailbox technology.
Terms of the Arrive acquisition of AirBox were not disclosed.
Merger Between Brüush and Arrive
On December 14, 2023, Brüush and Arrive entered into an agreement and plan of merger (the “Merger”). The business combination, conducted in the form of a reverse triangular merger via an all-stock transaction, includes the registration of the securities issued by the continuing combined company (“Combined Company”) upon the Merger closing. The Combined Company will focus on the advancement and implementation of Arrive’s smart Mailbox-as-a-Service (MaaS) platform that makes the exchange of goods between people, robots and drones frictionless through the use of artificial intelligence (“AI”). The Combined Company is expected to operate under the name Arrive Technology Inc., with its shares listed on the Nasdaq Capital Market under the ticker symbol ‘ARRV’. The Merger is expected to close in the first quarter of 2024, subject to customary closing conditions.
Additional details and support documents about the Merger have been provided in a Form 6-K filed by Brüush with the Securities and Exchange Commission (“SEC”) publicly available at www.sec.gov.
About Arrive Technology Inc.
Headquartered in Indianapolis, Indiana, Arrive (formerly Dronedek) is a technology company focused on facilitating the last inch of the last-mile for autonomous delivery. Founded by serial entrepreneur Dan O’Toole, Arrive’s smart Mailbox-as-a-Service (MaaS) platform makes the exchange of goods between people, robots and drones frictionless through the use of artificial intelligence (“AI”). Arrive’s patented smart mailbox system leverages climate-assisted cargo space, smart alerts and advanced chain of custody controls to secure the last inch of the last-mile for all shippers, delivery services and autonomous delivery networks. Arrive’s solutions are critically and uniquely positioned in the supply chain to leverage its unique data assets for artificial intelligence to provide users with machine-learning based insights that can aid businesses and consumers to lower logistical costs and capture new growth opportunities, among other benefits.
Over the last ten years, subscription companies have become all the rage. These are the companies that send you packages regularly consisting of items you have picked out or they have picked out for you.
BRSH CEO Aneil Manhas believes that the company has done an excellent job of creating a premium product for an affordable price. When you get your Brüush toothbrush, you can immediately tell it is a premium product.
Toothbrush heads should be replaced every 12 weeks — which makes BRSH’s subscription model that sends customers three new brush heads every six months (for about $22) a convenient way to stay on top of changing them.
They’ve grown considerably in popularity due to their convenience. Products range from foods and beverages to household goods, clothing, beauty, books, and more. There’s a subscription for almost everything.
Subscription businesses grew revenues about 5 times faster than S&P 500 company revenues (18.2% versus 3.6%), and U.S. retail sales (14.9% versus 2.3%) from 2012 to 2020.
$600 billion by 2026! How is BRSH aiming to take a piece of this market?
The rapidly growing, direct-to-consumer leader offers subscription-based, aesthetically pleasing electric toothbrushes and oral care products.
The company has a goal to become the go-to oral care brand for millennials and Generation Z, two substantial markets.
How big are these two markets?
Nearly half of Gen Z’ers (46%) and millennials (49%), for instance, were interested in subscriptions on average, compared with about a third (34%) of the general public. 4.7
As you can see with this striking revenue growth disparity, the transformative impact of the subscription model on modern business practice is huge. Looking ahead, the subscription economy is forecast to be worth.
Endorsed by Kevin Hart….
The Bruush toothbrush is a favorite of comedian and actor Kevin Hart who signed up to be company ambassador!
“Together, we are going to take Brüush to the next level of growth and break some of the norms of the category while we are at it.”
Aneil Manhas, the founder of the Company, has served as Chief Executive Officer since inception. Mr. Manhas has a career spanning over 15 years working in the financial services industry and in CEO positions of his previous companies
Recently, he was CEO of Surface 604, an electric bike company that he founded in 2015 and grew to be one of North America’s leading e-bike brands. He was also President and CEO of GVA Brands / Rosso Sports, a company he purchased in 2014 and transformed into Canada’s leader in entry-level powersports.
Mr. Manhas previously worked at Credit Suisse in Los Angeles, California for two years as an Investment Banking Analyst before joining Onex Corporation in Toronto, Ontario as a member of the investment team for five years, evaluating and executing large private equity transactions across multiple industries.
Aneil holds an Honours Business Administration (HBA) from the Richard Ivey School of Business at the University of Western Ontario.
Mandeek Manhas, Chief Financial Officer
Mandeek Manhas joined the Company in April 2023 as Chief Financial Officer to direct and oversee the Company’s finance department. Mr. Manhas has over 17 years of experience in a variety of leadership, managerial, financial, accounting, regulatory compliance, assurance, tax and advisory areas. This includes leading initiatives over operational and financial strategy, assessment of growth opportunities, governance and risk management.
Mr. Manhas joins the Company from Shape Properties, a real estate management, development and investment company with over $2.5 billion in asset value under management. As Director of Finance and Accounting for the income producing properties group, he led the finance and accounting functions through budgeting and forecasting, cash management, financial reporting, tax compliance, commercial support and overall growth of the portfolio of assets under management.
Previously, Mr. Manhas was Corporate Controller at Jervois Global (ASX: JRV, TSX-V: JRV), a dual-listed, multinational mining company with advanced development stage and exploration projects, where he led the finance department through a three-way merger with Ecobalt Solutions Inc. (TSX: ECS) and M2 Cobalt Corp. (TSX-V: MC). Prior to this, Mr. Manhas spent eleven years providing audit and advisory services with major accounting firms including Deloitte, Grant Thornton and Crowe MacKay, primarily working with small to mid-market cap corporations listed on Canadian and US exchanges.
Mr. Manhas is a Chartered Professional Accountant and holds a Bachelor of Commerce Degree from the University of British Columbia, with a double major in Finance and Accounting.
Alan MacNevin, Chief Operating Officer
Alan MacNevin joined the Company in June 2022 as Chief Operating Officer and leads the Company across all aspects of operations, driving strategic growth by directing and overseeing the scale of digital commerce, execution of strategic partnerships, launch of new products and expansion into new geographical markets. Mr. MacNevin has over 20 years of experience in executive-level positions managing large teams globally, while leading the growth at start-up e-commerce and subscription-based businesses and building them into category leaders.
Mr. MacNevin joins the Company from Rakuten Kobo, where over the past ten years he has held various executive positions including Chief Revenue Officer (2014-2015), Chief Marketing Officer (2015-2019), and most recently, Chief Operating Officer (2019-2022), where he managed the day-to-day global operations of the company. Driving growth, profitability and international expansion, Mr. MacNevin played a key role in Kobo’s emergence as a dominant player in the eReading industry.
Prior to joining Rakuten Kobo, Mr. MacNevin was a member of the executive team at Sirius Satellite Radio for six years from 2005 to 2011. At Sirius, Mr. MacNevin led the subscriber management team as the company grew from inception to over two million subscribers before it merged with XM Canada in 2011. Mr. MacNevin has also held senior marketing and operational roles at the Canadian Broadcasting Company, Chapters-Indigo Online and Bell Mobility.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY BRSH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
IN JUNE, THE FDA GRANTED FAST TRACK DESIGNATION FOR THE ACCLAIM-3 TREATMENT COMBINATION OF REQORSA AND TECENTRIQ AS MAINTENANCE THERAPY IN PATIENTS WITH ES-SCLC WHO DID NOT DEVELOP TUMOR PROGRESSION AFTER RECEIVING TECENTRIQ AND CHEMOTHERAPY AS INITIAL STANDARD TREATMENT
IN AUGUST, THE FDA GRANTED ORPHAN DRUG DESIGNATION TO REQORSA FOR THE TREATMENT OF SCLC
GENPREX COMPLETES A 1-FOR-40 REVERSE STOCK SPLIT EFFECTIVE FEBRUARY 2, 2024
BREAKING NEWS ANNOUNCED TODAY: GENPREX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A EXPANSION OF ACCLAIM-1 CLINICAL STUDY OF REQORSA® THERAPY IN COMBINATION WITH TAGRISSO® TO TREAT NON-SMALL CELL LUNG CANCER
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancerhttps://t.co/BXSw6ZbKeB
Thank you for taking the time to open up this email. We feel like we have something that warrants your immediate attention.
This is a company you are definitely going to want to research immediately.
Pull up GNPX right away.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans.
ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body.
The Company’s lead product candidate, REQORSA™ is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer.
Genprex’s diabetes gene therapy approach consists of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas.
In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.
In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.
There are several reasons why you should research this one right now but first and foremost is the reverse split that took place just last week. On the 2nd of February the company executed a 1 for 40 reverse split, drastically reducing the float. We generally see these Nasdaq’s lose some significant value following a reverse split. After 4 straight sessions to the downside we have witnessed this one level off today after some drastic swings. It appears to have found a floor and some support for the time being.
The company dropped some extremely encouraging news this morning which drove it all the way to 7.99 at the open:
GENPREX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A EXPANSION OF ACCLAIM-1 CLINICAL STUDY OF REQORSA® THERAPY IN COMBINATION WITH TAGRISSO® TO TREAT NON-SMALL CELL LUNG CANCER
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024
Acclaim-1 Study Has FDA Fast Track Designation
AUSTIN, Texas — (Feb. 5, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that in January 2024, the first patient was enrolled and dosed in the Phase 2a expansion portion of the Company’s Acclaim-1 clinical study of Reqorsa® Therapy (quaratusugene ozeplasmid) in combination with AstraZeneca’s Tagrisso® to treat patients with late-stage non-small cell lung cancer (NSCLC).
“We are encouraged by the very promising Phase 1 results in the Acclaim-1 trial, which demonstrated the combination of REQORSA and Tagrisso was well tolerated at all three dose levels with evidence of efficacy observed in patients with non-small cell lung cancer (NSCLC) whose disease has progressed on Tagrisso,” stated Mark Berger, Chief Medical Officer of Genprex. “We are excited to begin the Phase 2a expansion portion of Acclaim-1, which will examine the toxicity profiles of different cohorts as well as efficacy and other clinical endpoints.”
Data from the Phase 1 dose escalation portion of the Acclaim-1 study were presented at the 2023 AACR-NCI-EORTC International Conference for Molecular Targets and Cancer Therapeutics Meeting in October 2023. The data reported results from twelve patients with advanced, epidermal growth factor receptor (EGFR) mutant NSCLC whose disease progressed after Tagrisso treatment. REQORSA was generally well tolerated, as there were no dose limiting toxicities.
While the Phase 1 portion of the clinical trial was designed primarily to assess safety, promising efficacy results were also observed. One patient at the 0.06 mg/kg dose level, previously treated with carboplatin, pemetrexed, and Tagrisso, had a partial remission (PR) by investigator evaluation and treatment is now ongoing in the trial after 28 cycles, which is approximately 19.5 months. Another patient who is at the 0.09 mg/kg dose level, previously treated with Tagrisso, had stable disease and treatment was ongoing after 14 cycles, or approximately 10 months. And a third patient previously treated with cisplatin, pemetrexed, carboplatin, and Tagrisso at the 0.12 mg/kg dose level has stable disease and is continuing to receive REQORSA after 14 cycles, or approximately 10 months. The extended progression free survival (PFS) of each of these patients is consistent with long-term PFS seen in several patients in prior early stage clinical trials of REQORSA, and is not expected with treatment with Tagrisso alone after progression on Tagrisso1. PFS is the primary endpoint of both the Phase 2a expansion portion and the Phase 2b randomized portion of the Acclaim-1 study.
“Advancing Acclaim-1 marks an important milestone for Genprex. We are proud of the progress we have made thus far and are encouraged by REQORSA’s potential to improve outcomes for patients battling NSCLC. We look forward to an interim analysis from the Phase 2a study in 2025 and expect those results will further validate our novel gene therapy approach to treating lung cancer patients,” said Rodney Varner, President, Chairman and Chief Executive Officer at Genprex.
REQORSA, the Company’s lead product candidate, is being evaluated in three clinical trials as a treatment for NSCLC and small cell lung cancer (SCLC). Each of the three lung cancer clinical programs has received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of that patient population, and the SCLC program has also received an FDA Orphan Drug Designation.
About Acclaim-1 Clinical Trial
The Acclaim-1 clinical trial is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA, in combination with Tagrisso in patients with late-stage NSCLC with activating epidermal growth factor receptor (“EGFR”) mutations whose disease progressed after treatment with Tagrisso.
The Phase 1 dose escalation portion of the Acclaim-1 trial has been completed. The Phase 2a expansion portion of the study is expected to enroll approximately 66 patients, half of whom will have received only Tagrisso treatment and the other half will have received Tagrisso treatment and chemotherapy, to determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints. There will be an interim analysis following the treatment of 19 patients in each cohort. The Phase 2b randomized portion of the study is expected to enroll approximately 74 patients to be randomized 1:1 to receive either REQORSA and Tagrisso combination therapy or platinum-based chemotherapy. The primary endpoint of the Phase 2b portion of the trial is progression-free survival, which is defined as time from randomization to progression or death. An interim analysis will be performed at 28 events.
About Reqorsa® Therapy REQORSA® (quaratusugene ozeplasmid) for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (Genprex’s ONCOPREX® Nanoparticle Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells.
Genprex’s strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA’s unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers.
Tagrisso® is a registered trademark of AstraZeneca plc.Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024
Poised for FDA guidance regarding diabetes gene therapy program in 2024
AUSTIN, Texas — (January 5, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today provides a review of its 2023 achievements and a preview of plans for advancing its diabetes and oncology gene therapy programs in 2024.
“We are very proud of what we accomplished in 2023, particularly with the successful completion of the Phase 1 portion of our Acclaim-1 clinical trial in lung cancer,” said Rodney Varner, Chairman, President and Chief Executive Officer at Genprex. “In 2023, we also received a third Fast Track Designation for Reqorsa® Immunogene Therapy from the U.S. Food and Drug Administration, this time in combination with Tecentriq® for the treatment of small cell lung cancer, and REQORSA was also granted Orphan Drug Designation for the treatment of small cell lung cancer. We believe these designations underscore and further validate the potential of REQORSA. Our accomplishments in 2023, which also include process improvements in our manufacturing operations and securing new supplies of REQORSA, sets the foundation for a strong 2024.”
Oncology Gene Therapy Platform
Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Nanoparticle Delivery Systemwhich encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”), andeach of the three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population.
REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (programmed cell death) in cancer cells, and modulates the immune response against cancer cells. In early studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. Genprex’s strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA’s unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers.
Important events of the year included:
In April, at the 2023 Annual Meeting of the American Association for Cancer Research (AACR 2023), Genprex collaborators presented preclinincal gene therapy data with NPRL2, another tumor suppressor gene, that further validates the ONCOPREX Nanoparticle Delivery System as a platform
In December, Genprex completed the successful production of a new batch of REQORSA thereby securing REQORSA supply for its Acclaim clinical studies
Collaborators submitted abstracts in 2023 and are expecting to present data at the American Association for Cancer Research (AACR) Meeting in April 2024
Acclaim-1:
The Acclaim-1 study is a Phase 1/2 clinical trial that has three portions – a Phase 1 dose escalation which has been completed, a Phase 2a expansion, and a Phase 2b randomized portion. Acclaim-1 uses a combination of REQORSA and AstraZeneca’s Tagrisso® in patients with late-stage NSCLC that has activating epidermal growth factor receptor mutations and progression after treatment with Tagrisso. This novel approach to targeting lung cancer has demonstrated a strong safety profile with early signs of efficacy.
In May, Genprex completed the Phase 1 portion of the Acclaim-1 clinical trial and reported encouraging results. The Acclaim-1 Phase 1 study had no Dose Limiting Toxicities and results established a Phase 2 Recommended Dose, as well as provided data showing efficacy of REQORSA in combination with Tagrisso®
In May, after completion of the Phase 1 portion of the Acclaim-1 trial, the Safety Review Committee (“SRC”) approved advancement from the Phase 1 dose escalation portion of the trial to the Phase 2a expansion portion of the trial
In October, clinical collaborators presented a poster presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics showing the Phase 1 results of the Acclaim-1 study
In January 2024, Genprex expects to open the Phase 2a expansion portion of the Acclaim-1 study for enrollment
Genprex expects to complete the enrollment of 19 patients in each cohort of the Phase 2a expansion portion of the study by the end of 2024
Acclaim-2:
The Acclaim-2 study is a Phase 1/2 clinical trial that has three portions – a Phase 1 dose escalation portion, a Phase 2a expansion portion, and a Phase 2b randomized portion. The Acclaim-2 trial uses a combination of REQORSA and Merck & Co.’s Keytruda® in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. Patients are treated at the 0.06 mg/kg dose level in the first cohort of patients and, subject to the Acclaim-2 SRC approval, will be treated at successive dose levels of 0.09 mg/kg and 0.12 mg/kg.
Expanding on the previously granted patents in the U.S., Japan, Mexico and Russia, Genprex was granted patents in Australia, Chile and China to cover the use of REQORSA in combination with immune checkpoint inhibtors, e.g., PD1 and PDL1 inhibitors. These patents are applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials.
In the second half of 2024, Genprex expects to complete enrollment in the Phase 1 dose escalation portion of the Acclaim-2 study
Acclaim-3:
The Acclaim-3 study has two portions – a Phase 1 dose escalation portion and a Phase 2 expansion portion. In November 2022 Genprex filed with the FDA the protocol for the Phase 1/2 Acclaim-3 clinical trial using a combination of REQORSA and Genentech, Inc.’s Tecentriq® as maintenance therapy for patients with extensive stage small cell lung cancer (“ES-SCLC”) who develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.
In June, the FDA granted Fast Track Designation for the Acclaim-3 treatment combination of REQORSA and Tecentriq as maintenance therapy in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment
In August, the FDA granted Orphan Drug Designation to REQORSA for the treatment of SCLC
In January 2024, Genprex expects to open the Phase 1 portion of the Acclaim-3 study for enrollment, and expects to complete the Phase 1 portion of the study by the second half of 2024
In the second half of 2024, Genprex expects to start the Phase 2 portion of the Acclaim-3 study
Diabetes Gene Therapy Platform
Genprex’s diabetes gene therapy approach is comprised of an infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex has exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes. In October 2023, Genprex entered into a one-year extension to the August 2022 sponsored research agreement with the University of Pittsburgh. The extension includes a revised research plan to encompass the Company’s most recent technologies to which Genprex acquired exclusive rights from the University of Pittsburgh in July 2023. These include a MafB promoter to drive expression of the Pdx1 and MafA transcription factors that can potentially be used for both Type 1 and Type 2 diabetes. This research is expected to be initially conducted in a Type 1 animal model.
In February, Genprex’s research collaborators at the University of Pittsburgh presented preclinical data in a NHP model of Type 1 diabetes highlighting the therapeutic potential of GPX-002. These data, presented during an oral presentation at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023), showed statistically significant decreases in insulin requirements, increased c-peptide levels and improved glucose tolerance compared to baseline.
In April, the Company hosted a Key Opinion Leader virtual event, “Novel Gene Therapy to Treat Type 1 Diabetes,” which discussed preclinical data reported at ATTD 2023 supporting gene therapy to treat Ttype 1 diabetes
Finalized the components of the diabetes construct to take forward for nonclinical studies
In December, Genprex submitted a request to meet with the FDA to obtain their guidance on the nonclinical studies needed to file an Investigational New Drug application and initiate first-in-human studies. As a result of the FDA’s response, the Company will continue with its planned additional nonclinical studies before requesting regulatory guidance in 2024 for the IND-enabling studies.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Nanoparticle Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Research And Development Pipeline
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer https://t.co/zdKg4Vkebf$GNPX
– Addressing unmet medical need in large markets through the buildout of a robust pipeline of new drug candidates and drug combinations.
– Leveraging a gene therapy platform; Genprex’s non-viral ONCOPREX® Nanoparticle Delivery System is designed to deliver a variety of therapeutic genes to fight multiple types of cancer.
– REQORSATM immunogene therapy, the first systemically delivered gene therapy used for cancer in humans, can be combined with top-selling cancer drugs and may improve their benefits.
– Genprex has demonstrated clinical achievement with REQORSA in two clinical trials, showing a favorable safety profile and evidence of efficacy in lung cancer.
– GPX-002, Genprex’s diabetes gene therapy, works to transform alpha cells in the pancreas into insulin producing beta-like cells. A Phase 1 clinical trial could be the first-ever gene therapy tested in humans for diabetes.
– Advancing novel gene therapies in diseases with large markets and unmet needs.
– Two NSCLC trials currently enrolling; both with FDA Fast Track Designations.
– World class academic partners.
CLINICAL TRIALS
ONC-001
EVALUATING THE SAFETY OF REQORSA® IMMUNOGENE THERAPY AS A MONOTHERAPY (COMPLETED)
A Phase 1 dose escalation trial was conducted at The University of Texas MD Anderson Cancer Center evaluating the systemic, intravenous delivery of REQORSA® (TUSC2/FUS1) as a monotherapy in stage IV recurrent, metastatic lung cancer patients. The primary objective of this Phase 1 trial was to assess the toxicity of REQORSA administered systemically and intravenously, to determine the maximum tolerated dose, or MTD, and to determine a recommended Phase 2 dose of REQORSA alone.
THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS
The study showed for the first time that a tumor suppressor gene can be delivered systemically, intravenously and selectively to a patient’s cancer cells using a systemic nanoparticle vector. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients. REQORSA was well tolerated with tumor responses noted in lung primary and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous REQORSA selectively and preferentially targeted patients’ cancer cells.
Metabolic Tumor Response in a Metastatic Lung Cancer Subject
This subject survived after subsequent therapy more than seven years after the final treatment with REQORSA, to our knowledge, without evidence of cancer progression in the responding sites.
ONC-002
COMBINING REQORSA® IMMUNOGENE THERAPY WITH TARCEVA (ERLOTINIB)
PHASE 1 PORTION COMPLETED; PHASE 2 PORTION NO LONGER ENROLLING DUE TO OUR CHANGE OF FOCUS TO CONDUCT ACCLAIM-1
A Phase 1/2 clinical trial evaluated REQORSA® in combination with Tarceva® in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on Tarceva therapy. Patients without the EGFR mutation represent the vast majority of lung cancer patients. However, such patients generally are not candidates for Tarceva therapy.
In the Phase 2 trial combining REQORSA with Tarceva, subjects received REQORSA in combination with Tarceva every 21 days until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred first. We believe that the results from the Phase 2 trial are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is three months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of Gilotrif (afatinib) in a comparable group of patients.
REQORSA + Tarceva Combination: Phase 2 data in subjects with or without EGFR mutationsACCLAIM-1 COMBINING REQORSA™ IMMUNOGENE THERAPY WITH TAGRISSO (OSIMERTINIB) Preliminary analysis of the interim data from the Phase 2 portion of our ONC-002 trial supported our belief that REQORSA™ may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the U.S. Food and Drug Administration, or FDA. Data from our clinical trials, along with our preclinical data, provided the basis for our application for a Fast Track Designation, which was granted by FDA on January 14, 2020.In granting our Fast Track Designation, the FDA found that REQORSA may provide a benefit over existing therapies for patients whose tumors progress on AstraZeneca’s Tagrisso. The FDA Fast Track Designation is for use of REQORSA in combination with TKI Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with Tagrisso. We believe that the Fast Track Designation provides a clearly defined pathway toward FDA approval of the combination of REQORSA with Tagrisso.We initiated the Acclaim-1 clinical trial in June 2021, a Phase 1/2 clinical trial of REQORSA combined with Tagrisso. To learn more about Acclaim-1, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.ACCLAIM-2 COMBINING REQORSA™ IMMUNOGENE THERAPY WITH KEYTRUDA (PEMBROLIZUMAB) Researchers at MD Anderson Cancer Center have conducted preclinical studies evaluating REQORSA™ in combination with anti-PD1 checkpoint inhibitors, including Merck’s Keytruda.Positive and encouraging data indicate that REQORSA is synergistic with immunotherapies.In April 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2 with pembrolizumab, demonstrating that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells, that had metastatic lung cancer.In November 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2, pembrolizumab and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the combination of TUSC2 increases the effectiveness of pembrolizumab and chemotherapy, and thus, may improve on first-line standard of care for lung cancer.In May 2020, we entered into a worldwide, exclusive license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson for the use of TUSC2 in combination with immunotherapies, including Keytruda, and also for the use of TUSC2 in a three-drug combination of TUSC2, immunotherapy and chemotherapy.In December 2021, we received Fast Track Designation from the FDA for use of REQORSA in combination with the checkpoint inhibitor Keytruda for the treatment of advanced NSCLC patients whose tumors progressed after treatment with Keytruda.In March 2022, we opened the Acclaim-2 clinical trial for patient enrollment, a Phase 1/2 clinical trial of REQORSA combined with Keytruda. To learn more about Acclaim-2, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page. DIA-001STUDYING GPX-002 IN DIABETIC MICE Researchers at the University of Pittsburgh have conducted preclinical studies evaluating GPX-002 in diabetic mice models. In vivo mice studies have found that GPX-002 restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.These researchers are continuing to conduct preclinical studies in diabetic primates. Once sufficient preclinical data has been generated, we expect to begin a Phase 1 clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Pdx1/MafA Bibliography page. ONCOLOGY COMBINATION TREATMENT APPROACH Our oncology program uses a modern combinational treatment approach to fight cancer, utilizing our lead drug candidate, REQORSA™ immunogene therapy and our unique, proprietary, non-viral ONCOPREX® nanoparticle delivery system combined with approved targeted therapies and immunotherapies. This enables us to offer hope to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. ONCOLOGY COMBINATION TREATMENT APPROACH Our research indicates that when REQORSA, our lead drug candidate for non-small cell lung cancer (NSCLC), is combined with targeted therapies such as Tarceva (erlotinib) or Tagrisso (osimertinib) or with immunotherapies such as Opdivo (nivolumab) or Keytruda (pembrolizumab), REQORSA is synergistic with those drugs, meaning that the combination is more effective than either drug alone. We believe that by combining REQORSA with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer drugs into the large majority of patients who do not now benefit from them, either because the patients’ tumors do not have the molecular profiles that indicate effectiveness of those drugs, or because the patients have developed resistance to those drugs after receiving them for some period of time.To learn more about our combination trials utilizing our oncology combination treatment approach, refer to our Pipeline and Clinical Trials pages. TARGETED THERAPIES Targeted therapies work by targeting the cancer or disease’s specific gene, protein or tissue that contributes to the disease while sparing normal tissue. Unfortunately, targeted therapies require patients to have an activating genetic mutation specific to the drug. In NSCLC, the vast majority of lung cancer patients do not have the genetic mutations that qualify them for targeted therapies, such as the EGFR or ALK gene. In addition, the few patients who do have the genetic mutation qualifying them to receive targeted therapies are likely to develop resistance to these drugs over time.In January 2020, we received a United States FDA Fast Track Designation for use of REQORSA in combination with EGFR inhibitor Tagrisso for the treatment of NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. The median length of time that patients are treated with Tagrisso before their tumors progress is approximately eighteen (18) months. IMMUNOTHERAPIES Immunotherapy is a type of treatment that helps the immune system fight disease. Biomarker testing can help determine if high levels of PD-1/PD-L1 proteins are detected in the patient, signifying that the body’s immune system is not working to fight cancer or disease as it should. These patients could qualify for approved immunotherapies, however, not all patients benefit from immunotherapies.Genprex is conducting preclinical studies to evaluate REQORSA in combination with checkpoint inhibitors. Preclinical data indicate that Genprex’s lead drug candidate is synergistic with checkpoint inhibitors, such as Merck’s Keytruda, meaning that the combination of drugs may be more effective than checkpoint inhibitors alone. Preclinical data also indicates that a three-drug combination of a checkpoint inhibitor, chemotherapy, and REQORSA may be more effective than the two-drug combination of a checkpoint inhibitor and chemotherapy. MARKET OPPORTUNITY AstraZeneca’s Tagrisso had more than $4 billion in worldwide gross sales in 2020, and Tagrisso is AstraZeneca’s highest grossing product. Given Genprex’s Fast Track Designation and Tagrisso’s status as the current standard of care in EGFR-mutated NSCLC, we have prioritized the clinical development of REQORSA in combination with Tagrisso. We believe this regulatory pathway positions us well in the $17.9 billion global lung cancer market, especially given the advantages of our Fast Track Designation status.Merck’s Keytruda generated more than $14 billion in worldwide sales in 2020, and Keytruda is Merck’s highest grossing product. Keytruda is the standard of care in non-EGFR mutated NSCLC. Genprex plans to initiate a Phase I/II clinical trial evaluating REQORSA in combination with pembrolizumab. PROGRAMS LUNG CANCER CANCER Cancer is a complex disease that can start in any site in the body when a tissue grows out of control and inhibits the body’s normal functioning. At the cell level, cancer often involves the dysregulation of multiple genes and cellular pathways, leading to the cell’s inability to maintain proper cellular functions. Re-establishing or blocking these pathways can be done through many therapeutic approaches, including gene therapy. More general information about cancer can be found at The American Cancer Society.LUNG CANCERGenprex’s oncology program is focused on developing new treatments for cancer. Our initial therapeutic target is lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).According to the World Health Organization in 2020, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver, or stomach cancers. In 2020, there were more than 2 million new lung cancer cases and 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2022 there will be more than 236,000 new cases of lung cancer and more than 130,000 deaths from this disease. NSCLC represents 84% of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. SCLC represents about 13% of lung cancer patients and the five-year survival rate for patients with SCLC with distant spread is 3 percent. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC and SCLC in the United States and globally, and we believe REQORSA may be suitable for the majority of lung cancer patients. DIABETES Our diabetes gene therapy candidate, GPX-002, is being developed for the treatment of diabetes.According to the U.S. Center for Disease Control, 37 million Americans, or approximately 11% of the population, have diabetes. It is also believed that more than 96 million Americans have prediabetes, which represents approximately 38% of the U.S. population. The prevalence of this chronic disease is continuing to rise.Chronic diabetes conditions include Type 1 diabetes and Type 2 diabetes, both of which lead to excess sugar in the blood and can cause serious health problems. Left untreated, high blood sugar levels can damage eyes, kidneys, nerves, and the heart, and can also lead to coma and death.
TECHNOLOGY
REQORSA® IMMUNOGENE THERAPY
THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS
Our lead product candidate, REQORSA® immunogene therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda.
The active ingredient in our lead product candidate, REQORSA, is the TUSC2 gene, a tumor suppressor gene.
REQORSA consists of the TUSC2 gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance.
We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy used for cancer in humans.
OVERCOMING DRUG RESISTANCE
REQORSA is a pan-kinase inhibitor shown to simultaneously inhibit the EGFR and AKT oncogenic kinase pathways in vitro and in vivo. Once the cancer cell takes up the nanoparticle containing TUSC2, it is reprogrammed to die. Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that REQORSA’s multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops.
To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our Clinical Trials and TUSC2 Bibliographypages.
GPX-002
DIABETES GENE THERAPY
GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.
The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.
Image source: Osipovich, Anna & Magnuson, Mark. (2018). Alpha to Beta Cell Reprogramming: Stepping toward a New Treatment for Diabetes. Cell Stem Cell. 22. 12-13. 10.1016/j.stem.2017.12.012.
Diabetic mice studies show that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.
The diabetes gene therapy was developed by Dr. George Gittes, a researcher at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, where preclinical research is ongoing. GPX-002 has been tested in vivo in mice and nonhuman primates. Once sufficient preclinical data has been generated, we expect to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.
To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Clinical Trials and Pdx1/MafA Bibliography pages.
ONCOPREX® NANOPARTICLE DELIVERY SYSTEM
THE FIRST SYSTEMIC GENE THERAPY DELIVERY PLATFORM USED IN HUMANS FOR CANCER
Our oncology drug development program utilizes our unique, proprietary non-viral ONCOPREX Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with our initial product candidate, REQORSA® immunogene therapy.
DESIGNED TO DELIVER CANCER-FIGHTING GENES SYSTEMICALLY
The ONCOPREX platform has been designed and optimized to deliver cancer-fighting genes into the patient’s body systemically. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. Our nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and have been clinically shown to deliver molecular kinase inhibitors effectively.
OPTIMIZED PARTICLE SIZE
Our systemic, nanoparticle, non-viral delivery system, which is being used in our clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to be small enough to cross tight barriers in the lungs but large enough to avoid accumulation in the liver, spleen and kidney. The nanoparticles have been shown to be taken up by tumor cells after REQORSA administration at up to 33 times the rate they are taken up by normal cells. The cationic charge of the lipid nanoparticles targets cancer cells, which facilitates endocytosis. Once inside the cancer cell, the TUSC2 gene activates signaling pathways that result in cell destruction or apoptosis.
ENHANCED SAFETY AND EFFICACY DESIGN
We have administered REQORSA to more than 50 patients in Phase 1 and 2 clinical trials using our systemic, proprietary, non-viral delivery system.
A Phase 1 clinical trial showed that systemic, intravenous therapy using the ONCOPREX Nanoparticle Delivery System was shown to selectively and preferentially target primary and metastatic tumor cells, resulting in clinically significant anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.
Our earlier clinical trials have also shown that the ONCOPREX Nanoparticle Delivery System is well tolerated in humans and can safely deliver high therapeutic doses. We believe the ONC-001 clinical trial was the first systemic gene therapy clinical trial using a nanoparticle delivery system to deliver a tumor suppressor gene.
Genprex’s Diabetes Gene Therapy Program: A Major Step Forward in the Fight Against Type 1 Diabetes https://t.co/j1bZ1dlzZ1$GNPX
GENPREX (NASDAQ:GNPX) RELEASES NEW PATIENT VIDEO INTERVIEW DESCRIBING POSITIVE EXPERIENCE IN CLINICAL
AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is working with world-class institutions in developing new drugs from the company’s pipeline of gene therapy candidates in order to provide novel treatment approaches. Its oncology program utilizes its proprietary non-viral ONCOPREX® Nanoparticle Delivery System, which Genprex believes is the first systemic gene therapy delivery platform used for cancer in humans. The company’s lead drug candidate is called REQORSA®. The immunogene therapy (also known as quaratusugene ozeplasmid) is for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System. The drug may be helpful for treating patients who have already demonstrated drug resistance to other treatments.
On the heels of the release of recent positive safety and early efficacy data related to the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial for non-small cell lung cancer evaluating REQORSA in combination with Tagrisso, Genprex has released a new patient video featuring an NSCLC patient from the phase 1 portion of its Acclaim-1.
All patients in the trial had disease progression on their previous cancer treatment. In the video, an NSCLC patient who experienced extended Progression Free Survival (PFS) in the trial describes her positive experience taking REQORSA – Genprex’s lead drug candidate which she is still taking – while participating in the phase 1 portion of the Acclaim-1 clinical trial.
“While on REQORSA treatment, my doctor noted that the lung cancer lesions have not grown and there is no new growth,” said the NSCLC patient in the Phase 1 portion of Acclaim-1. “I believe the REQORSA treatment has benefited my life and has increased my time.”
The patient’s positive experience is encouraging – she was able to continue working full-time while participating in the clinical trial. She experienced only minor side effects from REQORSA and so far has experienced more than 10 months of progression-free survival.
NSCLC is the most common type of lung cancer, accounting for about 82% of all cases. While there have been some advances in treatment options for NSCLC, such as chemotherapy, radiation therapy and targeted therapies, the overall survival rate for patients with advanced NSCLC remains low. The five-year survival rate for patients with distant spread is 7%.
Genprex has disclosed favorable preliminary clinical data from the Acclaim-1 clinical trial’s phase 1 dose-escalation segment in an abstract published at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings show that REQORSA was well tolerated with no dose-limiting toxicities. Furthermore, Genprex reported preliminary evidence of efficacy in the phase 1 portion of the study.
“We are thrilled to have our abstract, which reports positive results from the phase 1 portion of our Acclaim-1 clinical trial, published at the ASCO Annual Meeting,” said Mark Berger, MD, Chief Medical Officer at Genprex. “We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed. In fact, the Safety Review Committee has just approved our advancement into the phase 2 expansion portion of the clinical trial.”
As noted above, the company also announced that its Safety Review Committee (SRC) has approved the advancement of the Acclaim-1 clinical trial to the phase 2 expansion portion of the trial. The SRC has examined the full safety data and has approved the recommended phase 2 dose of REQORSA, which is 0.12 mg/kg, twice the highest dose level delivered in Genprex’s previous clinical trials. This approval is a significant milestone in REQORSA’s development program. The SRC’s recommendation to advance the trial to the phase 2 expansion portion is a significant milestone for REQORSA.
Genprex’s REQORSA drug seems to be a promising innovation in cancer treatment. REQORSA’s unique approach of targeting the tumor suppressor gene TUSC2 sets it apart from other cancer treatments and other genetic medicines. Similar to companies like Bluebird Bio or Editas Medicine Inc., who are developing innovative therapies for rare diseases or using different gene editing techniques for cancer, Genprex’s REQORSA has the potential to be a game-changer in the field of cancer treatment through gene therapy.
Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer
Genprex announced the closing of its previously announced registered direct offering to healthcare-focused institutional investors of 7,425,744 shares of the Company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant. The offering was priced at-the-market under the Nasdaq rules.
Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. In this interview, Varner and Confer discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline.
Third FDA Fast Track Designation Further Validates the Potential of REQORSA
AUSTIN, Texas — (June 28, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF NINE THOUSANDUSDBY SICA MEDIA LLC FOR A ONE DAY GNPX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.